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CLSM   Confocal laser scanning microscopy 
CTAB   Cetyltrimethyl ammonium bromide 
DSC   Differential scanning calorimetry 
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In recent years nanotechnology-based drug delivery systems such as nanocrystals, 
polymeric nanoparticles, lipid nanoparticles, liposomes, nanoemulsions, 
microemulsions, nanofibers and dendrimers have shown promising results as novel 
drug delivery carriers. They offer a number of advantages such as improved drug 
solubility and stability, versatility to control drug release, improved membrane 
permeability of drugs, adjustable surface properties, drug targeting potential and 
flexibility to administering drugs via intravenous, intramuscular, subcutaneous and oral 
routes (D’Souza, 2014; Kesisoglou et al., 2007; Küchler et al., 2009b; Merisko-
Liversidge et al., 2003; Sahle et al., 2016; Yoo et al., 2011). Furthermore, nanoparticles 
can be used to target the skin surface, furrows and hair follicles (Figure 1).  
 
Figure 1: Sites in skin for nanoparticle delivery. Topical nanoparticle drug delivery takes place in three 
major sites: stratum corneum (SC) surface (panel a), furrows (dermatoglyphs) (panel b), and openings 
of hair follicles (infundibulum) (panel c). The nanoparticles are shown in green and the drug in red. Other 
sites for delivery are the viable epidermis (E) and dermis (D). (Reprinted from (Prow et al., 2011), 
Copyright (2011), with permission from Elsevier) 
                                            
1 Parts of this chapter were taken from:  
1. B. Balzus, F.F. Sahle, S. Hönzke, C. Gerecke, F. Schumacher, S. Hedtrich, B. Kleuser, R. Bodmeier, 
Formulation and ex vivo evaluation of polymeric nanoparticles for controlled delivery of 
corticosteroids to the skin and the corneal epithelium, Eur. J. Pharm. Biopharm., 115 (2017) 122-
130. 
2. B. Balzus, M. Colombo, F.F. Sahle, G. Zoubari, S. Staufenbiel, R. Bodmeier, Comparison of  
different in vitro release methods used to investigate nanocarriers intended for dermal application, 




Nanoparticles can potentially improve dermal local therapeutical efficiency by 
increasing drug penetration and permeation to the skin (Schafer-Korting et al., 2007; 
Shim et al., 2004). Nevertheless, until now there was just little success for nanoparticle 
mediated drug delivery to epidermis and dermis without barrier modification of healthy 
skin. However nanoparticles as drug delivery systems to improve dermal local 
therapeutical efficiency will be applied most likely to aged or diseased skin, where the 
barrier properties are changed. This might increase nanoparticle mediated drug 
delivery (Abdel-Mottaleb et al., 2012; Prow et al., 2011). 
 
1.1. Skin 
A main function of the skin is to protect the body against the external environment as 
physical barrier. Therefore the majority of environmental nanoparticles (viruses, dust, 
allergens or materials) cannot penetrate the skin unless the barrier is disrupted (Baroli, 
2010; Prow et al., 2011). Furthermore the skin absorbs IR and UV irradiation, regulates 
the temperature, prevents dehydration and defends the body from entering chemicals 
and biological agents. The immune and enzymatic system of the skin are additional 
cellular and molecular barriers to neutralize, attack or degrade everything that is not 
physically kept outside (Baroli, 2010; Honari and Maibach, 2014).  
 
1.1.1. Skin structure 
Skin consists of three layers: epidermis, dermis and hypodermis (Figure 2). For the 
penetration of the skin the epidermis and dermis are the only relevant ones (Honari 





Figure 2: Schematic picture of the native skin that is sub-classified into three main compartments: 
epidermis, dermis and subcutis (hypodermis). Skin appendices like hair with sebaceous glands, sweat 
glands as well as blood vessels are embedded in the skin. (Reprinted from (Mathes et al., 2014), 
Copyright (2014), with permission from Elsevier) 
The dermis has a capillary anastomoses function to supply the epidermis with nutrients 
and oxygen and clear the dermis from cell metabolic products and penetrated foreign 
agents. Above the dermis is the epidermis, which is separated from the dermis by a 
basement membrane (Woodley et al., 1983). 
The epidermis is dived in five strata: the stratum basale, which is in contact with the 
dermis, stratum spinosum, stratum granulosum, stratum lucidum (where present) and 
stratum corneum, which is in contact with the external environment. The epidermis has 
a barrier function and is classified as stratified squamous epithelial layer with 
keratinocytes, which differ between the layers due to progressive modification. 
Keratinocytes flatten, enucleate and differentiate to corneocytes while moving up from 
the stratum basale to the stratum corneum. This process takes around 14 days 
depending on the anatomic side and age and assists the elimination of pathogens, 
cancerous cells or solid particulate matter (Reddy et al., 2000; Roberts and Marks, 




undergo keratinization. The epidermis can simply be distinguished into the viable 
epidermis with keratinocytes and the stratum corneum with corneocytes, which are 
completely differentiated enucleated and keratinfilaggrin filled cells. The corneocytes 
are densely packed within a protein rich envelope with an outer lipid envelope 
surrounded by an extracellular lipid matrix arranged in bilayers (Mojumdar et al., 2016). 
Additionally the corneocytes are linked by corneodesmosomes, which maintain the 
cellular shape and regular packing of the corneocytes (Ishida-Yamamoto and Igawa, 
2014). The stratum corneum is covered by a thin layer of sweat, sebum, bacteria and 
dead cells. However, this thin layer is expected to have a negligible effect on the barrier 
properties. The diffusion through the stratum corneum is expected to be the rate 
limiting step in substance permeation across the skin (Prow et al., 2011). Inside the 
viable epidermis in the stratum granulosum the existence of functional tight junctions 
has been demonstrated (Brandner et al., 2002; Langbein et al., 2002). Tight junctions 
are regarded as another important element of the physical epidermal barrier system. 
Additionally constituent tight junction proteins have been identified in other epithelial 
layers and the hair follicles (Brandner et al., 2003).  
Besides the stratum corneum and the tight junctions as physical skin barriers the 
epidermis has a hydrophilic – lipophilic gradient with a nonhomogeneous change in 
hydrophobicity from the lipophilic stratum corneum to the hydrophilic stratum 
granulosum (Elias, 2005). This is an additional defense strategy to prevent penetration 
of lipophilic agents in the viable epidermis. Therefore a moderate oil water partition 
coefficient is a key parameter for transcutaneous absorption (Moss et al., 2002). 
Furthermore, there is a non linear pH gradient from stratum corneum surface (pH 4.5 
- 5.5) to the stratum corneum - stratum granulosum interface (neutral) (Schirren, 1955). 
The skin pH gradient and acid mantle are involved in the antimicrobial defense, 
permeability barrier homeostasis, stratum corneum integrity and cohesiveness, 
regulation of pH sensitive proteolytic enzymes, desquamation processes and 
restriction of inflammation due to the release of inhibition of pro-inflammatory cytokines 
(Schmid-Wendtner and Korting, 2006). The acid mantle and the pH gradient are 
maintained in a lipophilic environment due to the excretion of lactic acid from sweat 
glands, excretion of sebum triglycerides that are transformed in free fatty acids by the 




presence of membrane transporters for the exchange of sodium protons (Elias, 2005; 
Schmid-Wendtner and Korting, 2006).  
In summary the penetration of substances and particles in the stratum corneum and 
towards the viable epidermis is limited by the structure of the stratum corneum and by 
the gradients present in the epidermis. 
 
1.1.2. Sweat glands and pilosebaceous unit 
The sweat glands and pilosebaceous units are openings and shunts in the skin surface 
which can potentially be used as penetration route.  
Sweat glands are coiled tubular glands reaching from the stratum corneum down to 
the dermis or hypodermis (2 - 5 mm length). They are involved in the thermoregulation 
and excretion of acids and body wastes as sweat. Sweat is a hypotonic aqueous 
mixture of organic acids, carbohydrates, amino acids, nitrogenous substances, 
vitamins, and electrolytes and has a pH between 4.0 and 6.8 (Murota et al., 2015). 
The pilosebaceous unit is formed by the hair follicle with the associated sebaceous 





Figure 3: Morphology of the human hair follicle (Reprinted from (Patzelt et al., 2008a) Copyright (2008), 
with permission from Elsevier) 
It is reaching down to the dermis (2 – 4 mm length) so that penetrating agents could 
potentially reach the viable epidermis or the blood stream depending on the 
penetration depth of the agents. Hair follicles consist of an inner and an outer root 
sheet. The hair follicle starts with its orifice at the epidermis, which is followed by the 
infundibulum as the compartment of the upper hair shaft. The infundibulum is less 
densely cornified than the stratum corneum (Vogt et al., 2007). The sebaceous gland 
is attached to the hair follicle and is directed to the infundibulum in depth up to 500 µm 
(Vogt et al., 2005). The sebaceous gland is secreting sebum into the ducts and 
infundibulum with a sebum flow rate of 0.1 – 2.1 µg/cm2/min (Saint‐Leger and Cohen, 
1985). Sebum is a mixture of squalene, waxes, cholesterol derivatives, triglycerides, 
fatty acids and cell debris, which liquefy at 37 °C (Valiveti et al., 2008). However the 
composition of sebum is changing after secretion of the sebaceous gland. Triglycerides 
in the sebum composition undergo partial hydrolysis by bacterial lipases from the skin 
flora and epidermal esterases what liberates free fatty acids. These free fatty acids 




compartment between sebaceous gland and the hair bulb. Deep follicular areas reach 
down to the perifolliculum, where the hair shaft is surrounded by collagen fibers and 
the dermis. Large hair follicles of the scalp additionally exhibit arrector pili muscles 
(Poblet et al., 2002). The hair shaft is composed of different layers the cuticula, 
melanosomes, the cortex and the medulla. The deepest compartment the hair bulb 
consists of matrix cells, the papilla and germinative cells, which are supplied via blood 
vessels (Patzelt et al., 2008a).  
Hair follicles are classified in vellus, lanugo, sebaceous and terminal hair follicles 
depending on their orifice diameter, volume, surface and depth into the dermis. Vellus 
hair follicles reach down to 1000 µm depth into the dermis with hair shafts of 2 cm 
length and a thickness of less than 30 µm. Terminal hair follicles reach down to 3000 
µm depth into the dermis with characteristically pigmented hair that is longer than 2 cm 
and thicker than 50 µm (Vogt et al., 2007). The overall follicular density is specified as 
0.1% to the whole skin what usually refers to the forearm. In contrast the forehead 
displays 292 follicles/cm2 leading to a follicular orifice surface area of 13.7 mm2 which 
is 13.7% of the skin surface (Otberg et al., 2004). However only active hair follicles can 
be accessed. Hair follicles are active during hair growth, which takes years, or during 
sebum flow. Inactive follicles are closed and do not contribute to the follicular density 
and follicular penetration (Lademann et al., 2001).  
 
1.1.3. Skin diseases 
Skin diseases significantly change the barrier structure and function of the skin. Skin 
disease processes affect the dermal microenvironment associated with shifts in skin 
conditions like skin pH and transepidermal water loss. The physiological pH of healthy 
skin with an average of pH 5.5 is in some skin disease conditions like atopic dermatitis, 
ichthyosis, diaper dermatitis, irritant contact dermatitis and tinea pedis significantly 
increased depending on the severity of the disease (Ali and Yosipovitch, 2013). In 
patients with atopic dermatitis skin pH as high as 6.13 ± 0.83 was reported (Sparavigna 
et al., 1999). Besides the release of mediators the microbial colonization and 
inflammatory infiltrates can be altered (Hamid et al., 1994; Roll et al., 2004). 
Additionally, the localization and expression of tight junction proteins is disturbed by 




lesional skin with inflammatory disorders like in atopic dermatitis and psoriasis the 
differentiation process of keratinocytes, the biosynthesis of the stratum corneum, the 
lipid composition and the organization of the stratum corneum is changed resulting in 
an impaired barrier function (Schmuth et al., 2015; van Smeden and Bouwstra, 2016).  
Among skin diseases inflammatory skin diseases are the most common ones in 
medical dermatology and atopic dermatitis and psoriasis are the two most common 
inflammatory skin diseases (Guttman-Yassky et al., 2011). Atopic dermatitis and 
psoriasis can be easily distinguished clinically, because both exhibit distinct 
histological changes and an impaired barrier function. The percutaneous absorption 
rates of small molecules are increased in both cases (Garcia Ortiz et al., 2009; Lin et 
al., 2015). However, the increased skin penetration does not apply to all molecules 
(Yoshiike et al., 1993). Therefore diseased skin has rather a moderate increased 
penetration rate in comparison to healthy skin (Gattu and Maibach, 2011). Other 
challenging skin diseases are inflammatory processes in and around the hair follicle 
e.g. follicular psoriasis and primary inflammatory hair diseases. In these cases 




Topical corticosteroids are one of the most frequently prescribed drugs to treat 
inflammatory skin diseases by dermatologists. The clinical effectiveness of 
corticosteroids especially in the treatment of psoriasis and atopic dermatitis is 
mediated by their vasoconstrictive, anti-inflammatory, immunosuppressive and 
antiproliferative effects. The target cells of topical glucocorticoids are the keratinocytes 
and fibroblasts within the viable epidermis and dermis, where the glucocorticoid 
receptors are located (Marks et al., 1982; Ponec et al., 1981). The cellular uptake of 
corticosteroids is a non-mediated, passive diffusion (Ponec and Kempenaar, 1983). 
However certain target cells possess a specific transport system for corticosteroids 
(Rao, 1981). The immunosuppressive and anti inflammatory effects are related to the 
regulation of corticosteroid-responsive genes. Corticosteroids bind to the corticosteroid 
receptor forming a complex that is rapidly transported to the nucleus and binds to the 




transcription of certain genes and regulates thereby inflammatory processes (Hughes 
and Rustin, 1997). Corticosteroids also indirectly regulate gen transcription by blocking 
other transcription factors like nuclear factor κB (Scheinman et al., 1995). Furthermore 
corticosteroids inhibit the transcription of proinflammatory cytokine genes of interferon 
gamma, tumor necrosis factor alpha, interleukin-1,2 and 6. Additionally the T-cell 
proliferation and T-cell dependent immunity is inhibited (Almawi et al., 1991). In 
keratinocytes interleukin-1α inhibition has antiinflammatory effects, whereas in 
fibroblast interleukin-1α inhibition has antiproliferative and atrophogenic effects (Lange 
et al., 2000). The vasoconstrictive effect of corticosteroids additionally contributes to 
their anti-inflammatory activity and diminishes erythema at the lesion site. However, 
the exact mechanism is not completely clear. 
Despite the clear therapeutical benefit of corticosteroids in inflammatory skin diseases 
like atopic dermatitis and psoriasis (Furue et al., 2003) there are certain problems 
regarding corticosteroids. The treatment with topical corticosteroids is restricted to 
short therapy intervals, because of the facilitated penetration of topical corticosteroids. 
Long-term treatments on large skin surface areas lead to relevant absorption of 
corticosteroids in the organism and undesirable side effects in different organ systems. 
Undesirable side effects of topical corticosteroids are allergic reactions, skin atrophy, 
vasculopathy and an increased susceptibility to skin infections (Callen et al., 2007; 
Furue et al., 2003). Therefore, the disadvantage result from the chronic course of 
atopic dermatitis and psoriasis with recurrent episodes and long-term treatments with 
topical corticosteroids. Consequently there is a high demand for the development of 
novel therapeutic strategies that overcome these drawbacks and drug delivery to the 
intended site without further distribution to distant or irrelevant tissues is highly desired. 
In conclusion the development of delivery systems, which improve the selectivity of 
topical corticosteroid therapy, e.g. by targeted delivery of the corticosteroids to 
diseased skin areas and by prolonged release from reservoirs which maintain high 
corticosteroid concentrations at the site of action hereby allowing the reduction of the 





1.3. Drug penetration into the skin  
The opportunity to deliver bioactive molecules to the skin is not only an important 
implication for the local therapy of skin diseases but also for vaccination or systemic 
delivery of drugs with poor peroral bioavailability. Substances can penetrate across the 
stratum corneum transcellular, intercellular or through the appendageal pathway 
(Figure 4). 
 
Figure 4: Sketch of the three penetration pathways: intracellular, intercellular and follicular. The upper 
right inset is a close-up of the stratum corneum (SC) showing the intracellular pathway and the tortuous 
intercellular pathway (Reprinted from (Bolzinger et al., 2012) Copyright (2012), with permission from 
Elsevier). 
The intercellular route is favored especially for small molecules, which can freely move 
in the intercellular spaces. Therefore, the diffusion rate of small molecules is influenced 
by their physicochemical properties as lipophilicity, solubility, the hydrogen bonding 
ability molecular weight and volume (Potts and Guy, 1995). The transcellular pathway 
is unlikely compared to the intercellular route for most substances due to the repeated 




1979; Elias and Friend, 1975). Conventionally drugs are topical applied in creams and 
ointments however there are different investigations to overcome the skin barrier and 
enhance drug penetration especially for drugs, which hardly penetrate the skin due to 
their size or relative hydrophilicity.  
Drug penetration through the stratum corneum can be enhanced by substances in 
various ways e.g. chemically disturbance of the skin barrier (Ita, 2015),  by occlusion 
mediated skin hydration or by diffusion enhancement. Besides the critical discussed 
chemical disturbance (Finnin and Morgan, 1999) there are also physical methods to 
disturb the skin barrier and enhance drug penetration. Low frequency ultrasound 
temporally disturbs the skin barrier by shock waves (Azagury et al., 2014) and 
acoustically-induced microjets resulting from cavitation and electroporation with high 
voltage pulses temporarily creates aqueous pores in cell membranes (Blagus et al., 
2013). Furthermore the skin layer can be destroyed in a controlled manner by laser 
techniques which enhance drug penetration depth through artificial vertical channels 
(Sklar et al., 2014). Microneedle arrays mechanically damage the skin and form 
diffusion pathways for subsequently applied formulations. Microneedles can directly 
deposit the drug into the skin from immediately dissolving material or by hallow needles 
for microinjection (Haj-Ahmad et al., 2015; Sullivan et al., 2010; van der Maaden et al., 
2014). Nanoparticles are another alternative or addition to enhance the drug 
penetration into the skin. Nowadays, the potential of nanoparticles to overcome the 
skin barrier and penetrate into deeper skin layers is debatable. However studies are 
indicating that nanoparticles enhance drug penetration and permeation through the 
skin (Schafer-Korting et al., 2007) and even penetrate into deeper skin layers of barrier 
disrupted skin (Abdel-Mottaleb et al., 2012; Zhang and Monteiro-Riviere, 2008).  
 
1.4. Nanoparticles to enhance drug penetration into the skin 
Nanoparticles can be designed to interact differently with the skin, giving the 
opportunity of highly interesting clinical applications. Additionally, nanoparticles can 
facilitate distinct transport mechanisms that do not apply for dissolved bioactive 
molecules. Physicochemical properties of nanoparticles like size, shape, deformability, 
charge and polarity have significant effects on the ability to interact with the skin and 




compared to bigger nanoparticles (Liang et al., 2013). Spherical nanoparticles 
penetrate into the skin more rapidly than ellipsoid shaped nanoparticles (Ryman-
Rasmussen et al., 2006). Deformable nanoparticles penetrate better into the skin 
compared to rigid nanoparticles, because they are potentially squeezed between the 
corneocytes into deeper skin layers (Jose Morilla and Lilia Romero, 2016).  The 
negative skin charge under normal physiological conditions (Marro et al., 2001; 
Rojanasakul and Robinson, 1989) makes positively charged nanoparticles preferable 
for penetration due to electrostatic interaction. Negatively charged nanoparticles lack 
electrostatic interaction what impairs access to the outermost skin layer (Contri et al., 
2016; Wu et al., 2010). 
Another interesting advantage of nanoparticles is that they can control the drug release 
in contrast to the pure drug. Delayed drug release from nanoparticles allows better 
localization of the drug in the epidermis with low skin permeation tendency compared 
to conventional creams, what may significantly reduce local and systemic side effects 
associated with corticosteroid therapy and could improve treatment effectiveness and 
patient compliance (Abdel-Mottaleb et al., 2012; Abdel-Mottaleb et al., 2011). Recently, 
stimuli-responsive nanoparticles for dermal application such as pH- and temperature-
sensitive nanoparticles have received attention. pH-responsive nanoparticles can use 
pH-gradients on the skin between diseased and healthy skin to target the drug to higher 
pH disease sites and spare healthy skin areas by selection of nanoparticles with the 
desired pH threshold releasing at the pH of diseased skin but not healthy skin. Besides, 
the easy access to the skin surface gives the opportunity to use external triggers like 
UV light and heat to target diseased and spare healthy skin areas.  
 
1.5. Nanoparticles for follicular targeting 
The significance of the transfollicular route was long time doubtful, because hair 
follicles are only covering 0.1% of the skin surface and due to the sweat and sebum 
outward excretion (Lademann et al., 2001; Scheuplein, 1967). However the complex 
vascularization and deep invagination with a thinning stratum corneum of the 
pilosebaceous unit has led to a reappraisal of this view (Lu et al., 2014). Nowadays 
different studies are indicating that the transfollicular route has a significant effect on 




lipid nanoparticles and liposomes are known to penetrate into open hair follicles 
(Lademann et al., 2007) and a particle size of 300 – 600 nm is optimal for the follicular 
penetration, because this particle size correspond to the thickness of the overlapping 
cuticula hair surface (Lademann et al., 2009; Patzelt et al., 2011). In contrast 3 -10 µm 
microparticles enter only into the orifice or block the hair follicle (Teichmann et al., 
2006). Massaging also increases the penetration depth of nanoparticles, because the 
movement of the hair acts as a gearing pump that pushes the particles inside the hair 
follicle (Patzelt et al., 2011). In a mathematical simulation model it was demonstrated 
that the sawtooth-like profile of the hair surface together with a well-defined corrugation 
amplitude explain the enhanced particle transport into the hair follicle introduced by 
hair motion (Radtke et al., 2017). Hair follicles are an optimal target for drug delivery, 
because they represent an efficient reservoir for nanoparticles and nanoparticle based 
drug delivery as nanoparticles stay inside the hair follicle for several days (Lademann 
et al., 2006). However a barrier comparable to the stratum corneum in the upper hair 
follicle part and tight junctions in the lower part of the hair follicle prevent nanoparticle 
penetration into living tissue (Brandner et al., 2003; Nohynek et al., 2007). 
Furthermore, with time nanoparticles are eliminated from inside of the hair follicle to 
the skin surface by the outward sebum flow (Lademann et al., 2006). Targeting of the 
hair follicles with drug-loaded nanoparticles can be exploit for controlled drug delivery 
to maintain constant drug level within the tissue over several days for localized 
therapeutic action to reduce application frequency to increase patient compliance. 
Besides stimuli-responsive nanoparticles can be used to release the incorporated drug 
into adjacent target structures, like sebaceous glans, viable skin or vasculature 
(Lademann et al., 2016; Patzelt et al., 2017). Additionally dendritic cells and other cells, 
that are involved in inflammatory processes in the skin, can be targeted through the 
follicular route (Lademann et al., 2005; Vogt et al., 2005). Possible internal and external 
triggers in the hair follicle for stimuli responsive nanoparticles are pH, temperature, 
radiation and sebum. The temperature on the skin surface is around 32 °C (Burton, 
1935). Inside the hair follicle the temperature increases and is expected to reach the 
body temperature of 37 °C deep in the follicles. External radiation like IRA radiation 
can also be used for photo activated drug release as nanoparticles inside the hair 
follicle can still be reached by the radiation (Lademann et al., 2016). Additionally the 
composition of sebum represents a promising drug release trigger as sebum is mainly 




In conclusion nanoparticles can improve and control the drug penetration into the skin 
and effectively target hair follicles. As a result nanoparticles represent a promising 
option to improve topical therapy significantly, and at the same time reduce systemic 
side effects for skin and hair follicle associated diseases. 
 
1.6. Drug delivery systems for dermal application 
1.6.1. Nanocrystals 
The majority of the new developed drug molecules are poorly soluble and therefore 
often have a low bioavailability (Stegemann et al., 2007). Bioavailability problems are 
not only relevant orally, but also for the topical application to the skin. Low 
bioavailability is expected for drugs with a low saturation solubility and a low dissolution 
rate. Low dissolved drug amounts lead to a too low concentration gradient between 
formulation and skin and therefore allow drug diffusion into the skin (Müller et al., 
2011). A particle size reduction in general increase the kinetic saturation solubility and 
the dissolution rate (Buckton and Beezer, 1992). As a result nanocrystals were 
investigated to improve the bioavailability of poorly soluble drug molecules and since 
2000 there are some drug products on the market with nanocrystals for oral application. 
Nanocrystals consist to 100% of the active ingredient consequently the drug loading is 
practically 100%. In aqueous dispersions nanocrystals are generally stabilized by 
surfactants or a stabilizer layer (Rabinow, 2004). The dermal drug delivery of 
nanocrystals to improve skin penetration was not intensively investigated in the past. 
Nevertheless it was demonstrated that nanocrystals increase the drug penetration into 
the skin compared to coarse suspension and commercial formulations and additionally 
penetrate into the hair follicle (Corrias et al., 2017; Pireddu et al., 2016).  
 
1.6.2. Liposomes, ethosomes and transfersomes 
Liposomes, ethosomes and transfersomes are in general lipidic vesicles in the 
nanometer range that enhance the skin permeation of entrapped molecules (Cevc and 
Blume, 2001). These lipidic vesicles can be loaded with hydrophilic and hydrophobic 
drugs. Hydrophilic drugs are within the inner aqueous phase whereas hydrophobic 




are the poor colloidal stability. These particles tend to coalescence and fuse when 
submitted to dry environments, such as the skin surface (Schaller and Korting, 1996). 
Nevertheless there are some differences in their composition leading to differences in 
their physicochemical properties.  
Liposomes are vesicles of one or multiple lipid bilayers with an aqueous core. 
Generally liposomes are mixtures of phospholipids, or phospholipids and cholesterol 
and can be positively or negatively charged. Cholesterol leads to stiffer lipid bilayers 
and by increasing the cholesterol amount in liposomal compositions the deformability 
of liposomes decreases (Taylor et al., 1990). 
Ethosomes are lipidic vesicles with a fluid lipid bilayer and an increased elasticity due 
to the addition of 20 – 45% ethanol (Jain et al., 2007).  Ethanol interacts with the lipid 
polar heads and increases the fluidity of the liquid crystalline state of the phospholipids 
(Kurihara-Bergstrom et al., 1990). Besides, ethanol is a penetration enhancer to 
increase the skin penetration of the entrapped drug. Ethosomes are negatively 
charged due to the high ethanol amount (Touitou et al., 2000). The permeation of 
ethosomes is more effective than ethanol, aqueous ethanol or ethanolic phospholipid 
solution suggesting a synergetic effect between ethanol, vesicles and skin lipids 
(Touitou et al., 2000).  
Transfersomes are ultra deformable vesicles composed of phospholipids with 
surfactants, which act as edge activators to increase the elasticity and deformability of 
the lipid bilayer. The edge activators are generally single chain surfactants of high 
radius of curvature and mobility, like sodium cholate, sodium deoxycholate, Span 80, 
Tween 20 and Tween 80 (Jain et al., 2003). These particles are generally negatively 
charged. 
The different lipidic vesicular systems were studied with a broad range of different 
drugs to increase the drug penetration into the skin (Baroli, 2010). However, the clear 
mechanism how the lipidic vesicular systems increase the skin penetration of drugs is 
still unknown and there are different hypothesis.  
Lipidic vesicles are potentially squeezed through the corneocytes or interact with the 
thin sebum-sweat layer what could increase the particle adhesion to the stratum 




occlusive lipidic layer or rupture followed by the penetration of particle contents, which 
disorganizes the stratum corneum lipid matrix. The ingredients of the lipidic vesicles 
like lipidic esters, ethanol and surfactants are known penetration enhancers (Elsayed 
et al., 2007). Additionally it was demonstrated that lipidic vesicles penetrate into hair 
follicles and release the entrapped drug inside the hair follicles (Subongkot et al., 
2013). 
 
1.6.3. Lipid nanoparticles 
Lipid nanoparticles were developed to combine the advantages of nanoemulsions, 
liposomes and polymeric nanoparticles (Müller et al., 2002). Lipid nanoparticles are 
composed of solid lipids, which can be mixed with liquid lipids and are normally 
stabilized by surfactants. Lipid nanoparticles have generally an average particle size 
of 50 – 1000 nm, can be positively or negatively charged and are rigid due to their solid 
matrix. The lipids are generally well tolerated like in the case of nanoemulsions and 
liposomes (Mehnert and Mäder, 2001). Typically lipid nanoparticles are loaded with 
poorly water soluble substances and the loading capacity depends on the solubility of 
the substance in the lipids. The loading capacity reaches from below 1 % up to 50 % 
of very lipophilic substances like ubidecarenone (Jenning and Gohla, 2001; Westesen 
et al., 1997). The incorporated drugs are protected against degradation and the release 
of the active ingredient can be controlled due to the solid state of the particle matrix 
like in the case of polymeric nanoparticles (Zoubari et al., 2017). These particles are 
mainly intended for dermatological or cosmetic use. After application to the skin lipid 
nanoparticles adhere onto the skin and form an occlusive layer due to the large specific 
surface area of lipid nanoparticles (Dingler et al., 1999). The drug release of lipid 
nanoparticles and the drug partition into skin lipids can be controlled by the lipophilicity 
of the lipid matrix of the lipid nanoparticles (Küchler et al., 2010). However only a few 
intact lipid nanoparticles can be found in the first stratum corneum layers, because 
after topical application lipid nanoparticles are mixed with skin lipids and lose their 
morphology probably due to melting (Küchler et al., 2009b). Therefore the occlusive 
layer leading to an increased skin hydration is expected to be the primary reason for 




Additionally lipid nanoparticles frequently consist of lipids, which are also present in 
sebum. Sebum is the predominant environment in hair follicles. Therefore the hair 
follicles represent a potential penetration route for lipid nanoparticles and it was 
demonstrated that lipid nanoparticles based on lipids of sebum penetrate into the hair 
follicles and release the drug into sebum (Lauterbach and Müller-Goymann, 2014). 
 
1.6.4. Polymeric nanoparticles 
Polymeric nanoparticles were developed to control the release of the 
entrapped/encapsulated drug. Polymeric nanoparticles can be positively or negatively 
charged and the main polymeric nanoparticles investigated for dermal drug delivery 
can be classified in three groups i) large molecules with dendritic structures, ii) 
hydrophilic nanogels, i.e. polymer networks and  iii)  polymeric nanoparticles prepared 
by hydrophobic polymers, which form stable particulate carriers in an aqueous 
environment. 
Large molecules with dendritic structures are synthesized macromolecules, which 
exhibit a distinct molecular structure like dendrimers or dendritic (hyperbranched) 
architectures (Figure 5). 
 
Figure 5: Overview of dendritic architectures and their nomenclature (Reprinted from (Haag and Vogtle, 




The particle size of these dendritic structures can be optimized by the synthesis 
conditions and the selection of appropriate end groups for the synthesized 
macromolecules leading to stable nanoparticles without the need of surfactants. The 
structure-property-relationship was investigated with polyamidoamine dendrimers with 
varying functional surface groups (—NH2, —COOH, and —OH) and particle sizes 
between 10 and 18 nm. Polyamidoamine dendrimers penetrate the skin through 
intercellular lipids and hair follicles. Positively charged polyamidoamine dendrimers 
enhance the skin penetration more in comparison to negatively or neutral charged 
polyamidoamine dendrimers due to their higher affinity to the negatively charged skin. 
Furthermore the skin penetration is inversely correlated to the molecular weight of the 
nanoparticles and nanoparticle penetration could be detected up to the viable 
epidermis (Venuganti and Perumal, 2009; Venuganti et al., 2011). Nevertheless the 
toxicity of polyamidoamine dendrimers remains an issue and the preparation of less 
toxic degradable nanoparticles is under investigation (Uram et al., 2013). 
Hyperbranched nanoparticles like core multishell nanocarriers are composed of a 
hydrophobic and hydrophilic compartment and have a range in size from 20 - 30 nm. 
Core multishell nanocarriers consist of a dendritic polyglycerol core surrounded by an 
internal C18 alkyl shell and an outermost methoxy polyethylene glycol shell. Due to 
their structure, which is comparable to liposomes these nanoparticles can load 
hydrophobic and hydrophilic drugs and increase their delivery to viable skin layers 
(Küchler et al., 2009a; Küchler et al., 2009b). However, the drug loading is limited by 
the compartment volume available (Jansen et al., 1994). Additionally core multishell 
nanocarriers do not penetrate deep into the hair follicles due to their small size (Lohan 
et al., 2016). 
Hydrophilic nanogels are based on a hydrophilic polymer network with a defined 
dimension, which swells in aqueous environment e.g. N- isopropyl acrylamide and 
dendritic polyglycerols. Hydrophilic nanogels can load proteins like bovine albumin, L-
asparaginase II, or transglutaminase-1 with a loading capacity of up to 70 wt. %. N- 
isopropyl acrylamide dendritic polyglycerols are thermoresponsive. Therefore, 
nanogels were prepared, which collapse above 35 °C and release the loaded protein. 
These temperatures are typically reached within the deeper layers of the stratum 




delivery. However penetration of the nanogels themselves was not detected (Witting 
et al., 2015).  
Furthermore thermoresponsive nanogels were investigated for follicular drug targeting 
with triggered drug release. Therefore thermoresponsive nanogels with a particle size 
of 300 – 500 nm and different cloud points between 32 – 37 °C were prepared. These 
nanogels effectively penetrated and released the drug above their cloud points into 
hair follicles (Sahle et al., 2017). 
Polymeric nanoparticles prepared out of hydrophobic polymers are mainly used to 
encapsulate small hydrophobic molecules due to their probable affinity of matrix 
material and payload. The particle preparation and loading often occurs in one step by 
different physical methods like emulsion, nanoprecipitation or solvent displacement 
methods. Therefore these nanoparticles generally exhibit reasonable encapsulation 
efficiencies and drug loadings, because of the co localization of the polymer and the 
drug during preparation. Different polymers with different solubility, polarity, 
biocompatibility, biodegradability, swelling and charge can be used for the preparation 
of these polymeric nanoparticles. Eudragit®, cellulose, polylactic acid (PLA) and poly 
(lacitic-co-glycolic acid) (PLGA) derivates are among the most commonly used 
polymers for the preparation of nanoparticles.  
Eudragits are copolymers of methacrylic acid and methacrylic/ acrylic esters or their 





Figure 6: Chemical structure of different Eudragit® derivates (Reprinted from (Thakral et al., 2013) 
Copyright (2013), with permission from Taylor & Francis). 
These polymers are prepared by free-radical polymerization. The polymer chain length 
can be varied via various termination and transfer reactions. The polymerization can 
be done in solvent, emulsion, suspension, or even in bulk. The functional properties of 
Eudragit derivatives can be controlled by selecting from a variety of monomers. The 
non-functional co-monomers steer the polymer properties and the functional co-
monomer adjust the solution profile of the polymer. Eudragits have various applications 
in drug delivery systems. The cationic Eudragit® E is soluble below a pH of 5.5 and 
can be used for taste masking. Eudragit® L-55, L and S are anionic and soluble above 
pH 5.5, 6 and 7, respectively. These polymers are used as enteric coatings or for colon 
targeting. Eudragit® RL, RS, NE and NM are insoluble polymers and are used in 
sustained drug delivery systems. These polymers differ in their permeability properties 
due to different swelling behavior. Eudragit® RS is a positively charged, water-insoluble 
copolymer of ethyl acrylate, methyl methacrylate and a low amount of methacrylic acid 
ester with quaternary ammonium groups. It is commonly used in controlled drug 
delivery systems (Thakral et al., 2013). In dermal drug delivery, Eudragit® RS 
nanoparticle-based heparin gels controlled the drug release into the stratum corneum 
in comparison to a heparin solution (Loira-Pastoriza et al., 2012). Capsaicinoids-




adhesion and drug penetration in contrast to a capsaicinoids chitosan gel (Contri et al., 
2014).  
Cellulose-based polymers are also commonly used to prepare enteric coated, colon 
specific, controlled release and taste masked drug delivery systems. These polymers 
have a polymeric cellulose backbone which contains a basic repeating structure of β-
anhydroglucose units; each unit having three replaceable hydroxyl groups. The 
hydroxyl groups can be substituted with ether and ester groups to adjust the 
physicochemical properties of the resulting cellulose derivate (Figure 7). 
 
Figure 7: The molecular structure of cellulose and cellulose derivatives (Reprinted from (Rekhi and 
Jambhekar, 1995) Copyright (1995), with permission from Taylor & Francis). 
Cellulose ether derivatives are synthesized by mixing cellulose with sodium hydroxide. 
The resulting alkali cellulose can be etherified with alkyl halogens. Partially etherified 




cellulose are water soluble polymers and often used as gelling agents. High etherified 
cellulose derivatives like ethyl cellulose are water insoluble and can be used for 
controlled drug delivery systems. There are different viscosity grades of cellulose 
based polymers available. The viscosity of cellulose based polymer solutions 
increases with increasing length of the polymer molecule (Rekhi and Jambhekar, 
1995). In dermal drug delivery, quercitin-loaded ethyl cellulose nanoparticles controlled 
the drug release with increased quercitin skin retention (Sahu et al., 2013). 
Furthermore it is reported that ethyl cellulose nanoparticles selectively accumulate in 
inflamed skin, hair follicles and sebaceous glands (Abdel-Mottaleb et al., 2012). 
PLA and PLGA are biocompatible, biodegradable and safely administrable polymers 
approved by the Food and Drug Administration and European Medicines Agency. 
Therefore these polymers have widely been used in different drug delivery systems as 
implants, microparticles and nanoparticles. PLA is a synthetic polymer composed of 
lactic acid monomers, whereas PLGA is a synthetic copolymer composed of lactic acid 
and glycolic acid monomers (Figure 8).  
 
Figure 8: Polymers with hydrolysable chains: (a) Poly(glycolic acid); (b) Poly(lactic acid) and (c) Poly 
(D,L-lactide-coglycolide) copolymer (Reprinted from (Erbetta et al., 2012) Copyright (2012), with 
permission from Scientific Research Publishing). 
The polymer can be synthesized by various methods among - ring opening 
polymerization and polycondensation reactions are the major ones (Erbetta et al., 
2012). PLGA is biodegradable by hydrolysis leading to the metabolite monomers, lactic 
acid and glycolic acid. These monomers are eliminated from the body by the citric acid 
cycle (Anderson and Shive, 2012). PLGA and PLA are commercially available in 
different molecular weights and copolymer compositions. The degradation time of 
these polymers varies from several months to several years, depending on the 
molecular weight and copolymer ratio. The degradation rate of the polymer is effected 
by parameters such as molecular weight, the hydrophobicity (lactic acid > glycolic acid 




transition  temperature  of  the  amorphous  phase   (Vert et al., 1994; Visscher et al., 
1985, 1986). The forms of PLGA are usually identified by the monomers ratio used. 
For example, PLGA 50:50 identifies a copolymer whose composition is 50% lactic acid 
and 50% glycolic acid. In dermal drug delivery systems PLA and PLGA nanoparticles 
control the drug penetration and accumulation into the skin in comparison to the free 
drug (Luengo et al., 2006). Furthermore PLA and PLGA nanoparticles preferential 
accumulate in hair follicles due to their lipophilicity and reduced the transepidermal 
pathway by controlling the drug release (Rancan et al., 2009; Rancan et al., 2012). 
Nevertheless the PLGA degradation products lactic and/or glycolic acid cause a 
lowering of the local pH value and pH-values lower than 3 have been observed upon 
degradation, which is lower than the acidic milieu of the skin. Therefore the PLGA 
degradation could potentially have a negative effect on the pH homeostasis and the 
barrier function of the skin (Liu et al., 2006).  
Polymeric nanoparticles are prepared mainly by two different techniques: 
polymerization of monomers or dispersion of preformed polymers. Dispersion of 
preformed polymer is commonly realized by different methods including solvent 
evaporation, nanoprecipitation/solvent displacement, emulsification/solvent diffusion, 
salting out, dialysis or using supercritical fluid technology (Rao and Geckeler, 2011; 
Vauthier and Bouchemal, 2009). To choose an appropriate method, the solubility of 
the polymer and the drug in various solvents, safety and costs are considered (Rao 
and Geckeler, 2011; Yoo et al., 2011). The two most commonly used methods for the 
preparation of polymeric nanoparticles are nanoprecipitation/solvent displacement and 
solvent evaporation due to their simplicity. 
Nanoprecipitation is a simple, fast, reproducible and economic method, which unlike 
many other techniques, needs only a one step preparation. It does not require the 
formation of emulsions, but involves interfacial deposition of a polymer after 
displacement of a semi-polar solvent, miscible with water, from a polymer solution. 
Rapid diffusion of the solvent into the non-solvent phase leads to a reduction in 
interfacial tension between the two phases, what increases the surface area and result 
in the formation of small droplets of polymeric solution. At the end of the preparation 
the remaining solvent is either evaporated by continuous magnetic stirring or under 
reduced pressure (Rao and Geckeler, 2011; Vauthier and Bouchemal, 2009; Yoo et 




The solvent evaporation method is a simple and the most widely used technique to 
prepare polymeric nanoparticles (Rao and Geckeler, 2011). By this method, the 
polymer is dissolved in a solvent, which subsequently, is emulsified via high shear 
force or sonication into a phase, which is not miscible with the solvent to form an 
emulsion. Afterwards the solvent is evaporated, either by continuous magnetic stirring 
or under reduced pressure. 
 
1.7. Effect of the vehicle on nanoparticles and drug penetration 
Nanoparticles can be formulated in different vehicles like aqueous or organic solvent-
based dispersions, gel or cream. The different vehicle properties like vehicle viscosity 
and lipophilicity can have an effect on the nanoparticles and drug penetration. The 
diffusion coefficient of molecules inside the vehicle decrease with increasing 
viscosities. As a result viscous vehicles reduce drug skin partitioning and adsorption. 
The lipophilicity of the vehicle effects the drug partitioning into the stratum corneum 
and potentially influences the drug release behavior of the nanoparticle (Wenkers and 
Lippold, 1999). An occlusive effect of the vehicle may moderately increase the drug 
penetration due to a higher skin hydration (Zhai and Maibach, 2001). Other ingredients 
like solvents, surfactants and penetration enhancers may potentially alter or damage 
the stratum corneum and increase the penetration of some ingredients (Benson, 2005). 
After application of a nanoparticle formulation to the skin the formulation will change. 
Water and volatile ingredients will evaporate and non volatile ingredients are adsorbed 
to different extent. Furthermore, skin sweat and/or sebum components will interact with 
the applied formulation (Baroli, 2010). These effects could lead to destabilization/ 
agglomeration of the nanoparticles and the formation of supersaturated drug solutions 
with a potential drug recrystallization as larger microcrystals. In summary the 
formulation of nanoparticles with different physicochemical properties in different 
vehicles are critical parameters to achieve the desired drug release, drug penetration 





1.8. Characterization of nanoparticles 
Nanoparticle characterization include the determination of the particle size, particle 
morphology, zeta potential, drug loading, encapsulation efficiency and yield. 
Furthermore critical properties of nanoparticles are the drug release and their toxic 
potential as this are important factors to evaluate the therapeutical benefit. 
 
1.8.1. In vitro drug release methods 
In vitro drug release measurement is one of the most important methods used to 
assess the quality of a nanoparticle and to estimate its in vivo performance. In vitro 
and or in vivo release kinetics provide critical information about their behavior and are 
key parameter used to assess drug product safety and efficiency (D’Souza, 2014; Kroll 
et al., 2009).  
During the various stages of drug product development especially at the initial phase, 
in vitro release testing is an important analytical tool that enables a rational and 
scientific approach to drug product development (Moreno-Bautista and Tam, 2011). It 
can also reveal fundamental information on the dosage form and its behavior. 
Additionally in vitro drug release tests provide detailed information on drug release 
mechanisms and their kinetics and allows the establishment of an in vivo/in vitro 
correlation (D’Souza, 2014). Furthermore in vitro drug release tests are used as a 
compendial requirement, routine assessment of quality control to support batch 
release and to ensure batch to batch consistency under the SUPAC guidelines. 
To date, there is no compendial method or regulatory standard available to evaluate 
drug release from various pharmaceutical nanoparticles. Hence, several in vitro 
release methods, both compendial and non-compendial, have been utilized and 
reported. These methods can be broadly categorized in sample and separate, dialysis 
membrane, and in situ methods. The existing United States Pharmacopeia (USP) 
apparatus are primarily designed for in vitro drug release assessment of oral and 
transdermal products. Therefore there are many challenges when using compendial 
USP apparatus to investigate the release of nanoparticles. Certainly, the area of in 





In sample separation methods the nanoparticles are directly placed into the release 
media. The main release set-ups used are USP apparatus II (paddle) with volumes 
between 600 - 900 ml and vials with smaller volumes between 1 - 15 ml release media 
(Cetin et al., 2010; Sanna et al., 2012; Zhang et al., 2014). After certain time release 
media is withdrawn and needs to be physically separated from the nanoparticles to 
examine the released drug amount of the nanoparticles. In several investigations 
syringe filters are used to achieve physical separation between the release media and 
nanoparticles (Zhang et al., 2014). Besides, high energy separation techniques like 
centrifugation, ultracentrifugation, and ultrafiltration are used (Wallace et al., 2012). 
However, complete separation of the released drug from the nanoparticles is a 
concern, because it is challenging to separate particles that are less than a hundred 
nanometers in size and potentially shrink during the dissolution process like in the case 
of nanocrystals (Anhalt et al., 2012; Wallace et al., 2012). During filtration smaller 
nanoparticles may pass the filter so that a higher drug release is examined as in reality. 
Furthermore nanoparticles can clog the filter causing insufficient sample amounts for 
quantification (Kim et al., 1997). The disadvantage of centrifugation of nanoparticles is 
that it is time consuming and during centrifugation drug can be still released from the 
nanoparticles. 
The dialysis methods, which involve dialysis bags/tubes or a dialyzing membrane 
mounted in a Franz diffusion cell, are the most popular and common techniques to 
examine the drug release of nanoparticles (Ammoury et al., 1990; Heng et al., 2008; 
Montenegro et al., 2014; Moreno-Bautista and Tam, 2011; Souto et al., 2004; 
Venkateswarlu and Manjunath, 2004). In the regular dialysis bag method the 
investigated nanosuspension is placed into a dialysis bag that is subsequently sealed 
and placed in a larger vessel containing release media. The release media in the 
vessel is agitated to minimize unstirred water layer effects. The volume inside the 
dialysis bag is generally smaller than the outer release media. The released drug of 
the nanoparticles inside the dialysis bag diffuse through the membrane in the outer 
release media compartment from where samples are taken for analysis (Figure 9a) 
(Ammoury et al., 1990; Moreno-Bautista and Tam, 2011). In contrast, in the reverse 
dialysis set-up, the release media is placed into the dialysis bag and afterwards the 
bag is subsequently sealed and placed in a larger vessel containing the 




water layer and samples are taken from the inner compartment is sampled to 
determine the released drug amount (Figure 9b) (Xu et al., 2012).  
 
Figure 9: a) Dialysis bag method: The nanosuspension is placed into the dialysis bag and the dialysis 
bag is placed into the agitated release media. The sampling occurs from the outer release media. b) 
Reverse dialysis bag method: The release media is placed into the dialysis bag and the dialysis bag is 
placed into the agitated nanosuspension. The sampling occurs from the release media in the dialysis 
bag. c) Side-by-side dialysis: The nanosuspension and the release media are vertically separated by a 
dialysis membrane. The sampling occurs through a sampling port on top of the release media 
compartment. d) Franz diffusion cell: The nanosuspension is placed on top of the Franz diffusion cell in 
the donor compartment. The release media is horizontally separated by a membrane. The sampling 
occurs through a sampling port from the release media compartment. 
In the side-by-side dialysis, the donor and receiver cell are vertically separated by a 
dialysis membrane and generally contain equal volumes of media. The sampling 
occurs from the receiver cell. The advantage is that both compartments can be stirred 
with a magnetic stirrer (Figure 9c) (Chidambaram and Burgess, 1999). In the Franz 
diffusion cell the sample is placed on top of the cell into the donor compartment, which 
is horizontally separated by a dialysis membrane or excised skin to the acceptor 




and the sampling occurs through a sampling port from the acceptor compartment 
(Figure 9d) (Souto et al., 2004). In contrast to the other dialysis methods the Franz 
diffusion cell can be used with excised skin instead of a dialysis membrane. Therefore, 
drug penetration and permeation into and through the skin can be examined ex vivo 
with Franz diffusion cell. Furthermore, Franz diffusion cell unlike the dialysis tubes and 
the side-by-side dialysis can be easily used with semisolid dosage forms of 
nanoparticles. 
The disadvantage of the dialysis methods is that basically a dialysis membrane retains 
the nanoparticles and allows the transfer of the released drug into a receiver 
compartment (Venkateswarlu and Manjunath, 2004). So that, due to two diffusional 
barriers, the measured drug release kinetics will be artificially decreased, and 
depending on the drug/carrier systems, significant errors may be introduced by the 
membrane (Moreno-Bautista and Tam, 2011; Washington, 1989; Zambito et al., 2012). 
Particularly when the actual rate of drug release from the drug carriers is faster than 
the rate of diffusion out of the dialysis membrane, the experimental data do not fully 
reflect the actual release profile of the drug. It is also not possible to capture a potential 
initial burst release from the colloidal drug carriers. Therefore, a dialysis membrane 
with a low diffusional barrier and a low affinity for the drug should be used. 
Nevertheless, this method can still be used as a general guide in drug delivery 
research, because differences in equilibration time can be used as discriminatory tool 
to study the release behavior between fast and slow releasing dosage forms (Kim et 
al., 1997). Precise release kinetics assessment may also be attained by using 
mathematical models to compensate for the delay in drug diffusion due to the dialysis 
bags (Moreno-Bautista and Tam, 2011).  
In situ drug release measurements lack the problems associated with sample 
separation or diffusion barriers. Accordingly, a number of novel in situ release methods 
based on different working principles, such as differential pulse polarography 
(Rosenblatt et al., 2007), voltametry and turbidimetry (D’Souza, 2014; Moreno-Bautista 
and Tam, 2011) and light scattering (Anhalt et al., 2012) were reported. 
Electrochemical methods can be used for rapid in situ measurements of released drug 
while avoiding the interference caused by the presence of undissolved dosage form in 




are limited to a certain group of compounds, for example ionizable drugs, or require 
instruments that are more sophisticated.  
Non-electrochemical methods like calorimetry, turbidimetry, and laser diffraction have 
also been evaluated as in situ release methods. The principle of the calorimetric 
measurement is based on detection of the net proportion of heat change during in vitro 
release. Concerns with calorimetric measurements are long equilibration times and 
that the heat produced by all the processes needs to be considered (Kayaert et al., 
2010). Turbidimetric and laser diffraction approaches are based on the change in light 
scattering properties of nanoparticles dispersed in release media. Dissolution kinetics 
of nanocrystals of different sizes ranging from 120 - 270 nm could be examined and 
distinguished by the light scattering method (Anhalt et al., 2012; Crisp et al., 2007). 
Challenges of these methods are the long equilibration times, limited range of particle 
size, and initial concentration of samples that can be used.  
Another alternative method is the in situ drug release measurement with a Sirius® 
inForm apparatus. This apparatus can measure the UV absorbance of the released 
drug without separating it from the nanoparticles (Colombo et al., 2017). Since 
nanoparticles cause a significant light scattering, which alter the UV spectra (Van 
Eerdenbrugh et al., 2011), the instrument makes adjustments for the amount of UV 
light lost using the concepts of Tyndall-Rayleigh scattering theory. However, this 
feature makes the method susceptible for errors, especially when used with highly 
turbid samples. 
In summary, different techniques can be used to assess drug release from 
pharmaceutical nanoparticles, which may give different results as the methods are 
different in their working principles. Even with the same method different results might 
be obtained when working under sink and non-sink conditions (Mishra et al., 2009; 
Murdande et al., 2015). However in general non-sink conditions are reported to be 
more discriminative than sink conditions when investigating nanoparticles (Liu et al., 
2013). The main problem is that the choice of a drug release method for analysis of 
nanoparticles in most cases is random without giving an account about their 
reproducibility and ability to discriminate release between different dosage forms. 
Furthermore, little information is available with regard to comparability of different in 




1.8.2. Determination of nanoparticle and drug penetration into the skin 
The investigation of nanoparticle and drug penetration into the skin is essential for the 
development and optimization of new dermal pharmaceutical products. Different 
models have been established to investigate skin penetration of drugs and 
nanoparticles. Normally the ex vivo drug penetration is investigated with excised 
human skin from surgeries. The excised skin is placed onto Franz diffusion cells 
between the donor and acceptor compartment instead of the membrane to investigate 
the drug penetration. The drug amount which permeates through the skin reaches the 
acceptor compartment and can be quantified in the same. The drug amount which 
penetrates into the different skin layers can be quantified at the end of the experiment. 
The used excised human skin can be separated by heat into epidermis and dermis, 
which can be extracted afterwards to quantify the penetrated drug amount (Döge et 
al., 2016). 
Another approach to quantify the drug amount in the different skin layers is the tape 
stripping method. Tape stripping is a simple method which is used for penetration 
studies for decades (Lademann et al., 2012). In this method adhesive films are 
successively applied to and removed from the skin after topical application of the 
investigated formulation. Each tape removes corneocytes layer by layer and 
subsequently the penetrated drug or nanoparticle amount in the respective layer. 
Afterwards the amount of removed corneocytes (stratum corneum) can be quantified 
by weighing (Weigmann et al., 1999). As a result every used tape strip contains two 
types of information: the amount of stratum corneum and the concentration of the 
topically applied substance in the respective layer. The drug concentration can be 
quantified for example after extracting the tape with solvents by UV or HPLC. 
Additionally the penetration depth of nanoparticles can be determined semi 
quantitative by fluorescence microscopy for example in the case of fluorescence 
labeled nanoparticles. Those information are used to examine the penetration depth 
profile of nanoparticles and/or the drug. However tape stripping can only remove the 
dead cells of the stratum corneum. The information about the penetrated drug amount 
into the living tissue is not provided. Nevertheless tape stripping can be performed 




To differentiate the penetrated drug amount in the stratum corneum and hair follicles 
differential tape stripping was developed (Teichmann et al., 2005). This method 
combines the tape stripping method with a cyanoacrylate biopsy. After removing the 
penetrated drug amount from the stratum corneum by tape stripping the remaining 
drug amount in the hair follicle is extracted by a cyanoacrylate biopsy, which takes up 
the hair follicle contents. 
However excised human skin has the disadvantage that follicular penetration cannot 
be investigated, because it contracts after surgical removal. The very dense network 
of elastic fibers around the hair follicle keeps the hair follicle closed even after 
stretching the excised skin. In contrast to excised human skin pig ear skin does not 
contract after removal due to the cartilage where it is fixed. Furthermore porcine ear 
skin has a hair density of 11 – 25 hairs/cm2 with a diameter of 58 – 97 µm and an 
infundibular diameter of 200 µm while the infundibulum reaches a depth of 550 µm and 
sebaceous glands may be associated in a depth of about 500 µm which is comparable 
to human skin (Jacobi et al., 2007). Therefore pig ear skin represents a good model to 
investigate ex vivo nanoparticle and drug penetration into hair follicles. 
 
1.8.3. Safety/Toxicity 
The characterization of the toxicological potential of nanoparticles is an important 
property to assess the clinical potential of such innovative drug delivery systems. The 
broad variety of nanoparticles can mainly be classified according to their toxicological 
potential into less toxic nanoparticles and critical nanoparticles which might exhibit 
toxicity due to certain physicochemical properties. Soluble and or/ biodegradable 
nanoparticles disintegrate after application to skin into molecular species, like 
liposomes and PLGA nanoparticles and are supposed to be less toxic. In contrary 
insoluble and/or biopersistent nanoparticles, like quantum dots and fullerenes, can be 
taken up by and remain in the reticulo-endothelial system and cells especially after 
application repetition. Therefore those nanoparticles are supposed to exhibit a higher 
toxicity (Bowman et al., 2010). 
Uptake of nanoparticles in keratinocytes of the stratum corneum occurs most likely 
through specialized processes like endocytosis on recognition by lipid rafts (Zhang and 




distribute throughout the cytosol and localize in the perinuclear region without any toxic 
effects (Teskac and Kristl, 2010).  
Besides this classification, nanoparticles can be characterized upon their cytotoxic and 
oxidative stress induction effect, which are two of the major concerns inducing toxic 
and genotoxic effects. The cytotoxic potential can be examined for example by the 
MTT assay. The MTT assay is a widely used method to determine the viability in 
metabolic active cells. It is based on the conversion of the yellow MTT to formazan 
blue by the mitochondrial reductase system of living cells. Dead cells can not reduce 
the yellow MTT and the color difference can be quantified to examine the amount of 
dead cells and the cytotoxic potential. The oxidative stress triggered by nanoparticles 
can be examined for example by measuring the intracellular reactive oxygen species 
(ROS) with the H2DCFDA assay. H2DCFDA is a chemically reduced, acetylated form 
of fluorescein used as an indicator for ROS in cells. This nonfluorescent molecule is 
deacetylated by intracellular esterases and can be oxidized to fluorescent 
dichlorofluorescein by radicals such as hydroxyl, peroxyl, alkoxyl, nitrate and 
carbonate to a fluorescent molecule and quantified by fluorescence measurements. 
 
1.9. Research objectives 
The purpose of this work was to prepare nanoparticles which potentially increase 
treatment effectiveness and minimize corticosteroid associated side effects to improve 
patient compliance by controlled drug release into the skin and hair follicles. 
Additionally different in vitro drug release methods for nanoparticles should be 
compared.  
The specific goals were: 
• To prepare dexamethasone-loaded polymeric nanoparticles which adhere well 
to the skin and release the drug slowly in a controlled manner. 
• To prepare dexamethasone-loaded polymeric nanoparticles, which penetrate 
deep into the hair follicle and release the drug within the hair follicle triggered 
by their dissolution in sebum. 
• To optimize the dexamethasone-loaded polymeric nanoparticles regarding their 




• To assess and compare the reproducibility and discriminative power of three in 
vitro drug release methods under sink and non-sink conditions for nanoparticles, 
namely dialysis bags, Franz diffusion cells and an in situ drug release method 
using Sirius® inForm apparatus. 
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2. Materials and methods 
 
2.1. Materials 
2.1.1. Drug, drug formulation and dye 
Dexamethasone (Fagron GmbH & Co. KG, Barsbuettel, Germany); DEXAMETHASON 
Creme LAW; 0.05% (Riemser Pharma GmbH, Greifswald, Germany); Nile red (Sigma-
Aldrich GmbH, Schnelldorf, Germany) 
 
2.1.2. Polymers 
Ethyl cellulose (Ethocel® Standard 4 Premium, Colorcon Ltd., Dartford, UK); 
poly(methacrylic acid-co-methyl methacrylate, 1:1) (Eudragit® L 100), poly(methacrylic 
acid-co-methyl methacrylate, 1:2) (Eudragit® S 100), ammonio methacrylate 
copolymer type B (Eudragit® RS 100), PLGA 503 H, (Evonik Industries AG, Darmstadt, 
Germany); hydroxypropyl methyl cellulose phthalate 55 (HPMCP-55), (Shin-Etsu 
Chemical Co., Ltd., Tokyo, Japan); hydroxyethyl cellulose (HEC), (Natrosol® 250 HX, 
Ashland Industries Europe GmbH, Schaffhausen, Switzerland); PLA (PURASORB 
PDL 02, Corbion, Amsterdam, Netherlands); PLGA 503 (Resomer  503), PLGA 502 S 




Stearoyl macrogolglycerides (Gelucire® 50/13, Gattefossé GmbH, Bad Krozingen, 
Germany); solid triglycerides containing hydrogenated coco-glycerides, beeswax and 
ceteareth-25 as additive (Witepsol® S55, Cremer Oleo GmbH & Co. KG, Hamburg, 
Germany); cetyl palmitate, olive oil, palmitic acid, squalene (Carl Roth GmbH & Co. 
KG, Karlsruhe, Germany); liquid paraffin (Caesar & Loretz GmbH, Hilden, Germany); 
cotton seed oil, coconut oil (Sigma-Aldrich GmbH, Schnelldorf, Germany); cholesterol, 
oleic acid (Alfa Aesar GmbH & Co KG, Karlsruhe, Germany); paraffin (solidification 
point 57-60 °C) (Merck KGaA, Darmstadt, Germany) 
 




Poloxamer 188 (Kolliphor® P188), poloxamer 407 (Kolliphor® P407) (BASF SE, 
Ludwigshafen, Germany); polyvinyl alcohol 4-88 (PVA) (Emprove®, Merck KGaA, 
Darmstadt, Germany); polyethylene glycol sorbitan monooleate (Tween® 80), sodium 
deoxycholate (Carl Roth GmbH & Co. KG, Karlsruhe, Germany); cetyl 
trimethylammonium bromide (CTAB) (Sigma-Aldrich GmbH, Schnelldorf, Germany) 
 
2.1.5. Reagents and kits 
Disodium hydrogen phosphate dodecahydrate (Merck KGaA, Darmstadt, Germany); 
sodium chloride, potassium dihydrogen phosphate, ethyl acetate, fluorescence-
activated cell sorting (FACS) buffer (PBS containing 0.5% BSA and 0.1% NaN3), 
sodium dodecyl sulfate (SDS) (Carl Roth GmbH & Co. KG, Karlsruhe, Germany); 
phosphate buffered saline (PBS) (Dulbecco; BIOCHROM GmbH, Berlin, Germany); 6-
carboxy-2´,7´-dichloro dihydrofluorescein diacetate (H2DCFDA) (Molecular Probes 
Inc., Darmstadt, Germany); keratinocyte growth medium (KGM) supplemented with 
Bullet Kit (Lonza AG, Cologne, Germany); silver nanoparticles 40 nm, 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) (Sigma-Aldrich GmbH, 
Schnelldorf, Germany); dexamethasone-4,6α,21,21-d4 (C/D/N ISOTOPES Inc., 
Quebec, Canada); acetone, acetonitrile (VWR International GmbH, Darmstadt, 
Germany); trypsin (PAA Laboratories GmbH, Pasching, Austria);  Piperazine-N,N′-
bis(2-ethanesulfonic acid) (PIPES) buffer (Ampliqon A/S, Odense, Denmark) 
All other reagents and solvents used were of analytical grades. Ultra-purified water 
purified by a Milli-Q® apparatus (Millipore GmbH, Darmstadt, Germany) was used. 
 




2.2.1. Particle preparation 
2.2.1.1. Nanocrystals 
Dexamethasone nanocrystals were prepared by wet bead milling. Dexamethasone 
was suspended in an aqueous surfactant solution and homogenized by an Ultra Turrax 
(T25, IKA® -Werke GmbH, Staufen, Germany) at 20,500 rpm for 30 s. 0.1 mm 
zirkonium beads (Hosokawa Alpine AG, Augsburg, Germany) and the suspension 
(suspension:beads, 1:3 w/w) were added into a 100 ml erlenmeyer flask and milled for 
3 h under magnetic stirring at ~800 rpm. The nanosuspension was filtered through a 
1.2 µm glass microfiber filter (Whatman® GE Healthcare UK Ltd., Buckinghamshire, 
UK) to exclude larger particles. 
After preparation, whenever necessary, nanocrystals were formulated into gels by 
using 2.5% and 5.0% (w/w) HEC. 
 
2.2.1.2. Polymeric nanoparticles 
Dexamethasone-loaded ethyl cellulose, Eudragit® RS and ethyl cellulose/Eudragit® RS 
nanoparticles were prepared by the solvent evaporation method. The drug and the 
polymer were dissolved in ethyl acetate and the polymeric drug solution was emulsified 
in 30 ml aqueous surfactant solution via high shear homogenization using an Ultra 
Turrax at 8,000 rpm for 10 s and then at 9,500 rpm for 20 s. The emulsion was 
sonicated (Bandelin Sonopuls HD 3200, Bandelin electronic GmbH & Co. KG, Berlin, 
Germany) at 200 W (amplitude 50%, tip MS73) for 3 min in an ice bath and ethyl 
acetate was removed by continuous stirring of the dispersion overnight under a fume 
                                            
2 Parts of this chapter were taken from:  
3. B. Balzus, M. Colombo, F.F. Sahle, G. Zoubari, S. Staufenbiel, R. Bodmeier, Comparison of  
different in vitro release methods used to investigate nanocarriers intended for dermal application, 
Int. J. Pharm., 513 (2016) 247-254  
4. B. Balzus, F.F. Sahle, S. Hönzke, C. Gerecke, F. Schumacher, S. Hedtrich, B. Kleuser, R. Bodmeier, 
Formulation and ex vivo evaluation of polymeric nanoparticles for controlled delivery of 
corticosteroids to the skin and the corneal epithelium, Eur. J. Pharm. Biopharm., 115 (2017) 122-
130. 
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hood. Afterwards, the remaining organic solvent was removed at 40 °C using a rotary 
evaporator (BUECHI rotavapor-R, BÜCHI Labortechnik AG, Flawil, Swizerland). The 
colloidal dispersion was first filtered through a 1.2 µm and then 0.7 µm glass microfiber 
filter (Whatman® GE Healthcare UK Ltd., Buckinghamshire, UK) to exclude lager 
particles. Drug-free or Nile red-loaded nanoparticles were prepared by the same 
procedure without the drug and instead of the drug dissolving Nile red in the polymer 
solutions, respectively. 
After preparation, whenever necessary, polymeric nanoparticles were formulated into 
gels by using 2.5% and 5.0% (w/w) HEC. 
 
2.2.1.3. Lipid nanoparticles 
Dexamethasone-loaded lipid nanoparticles were prepared by high shear 
homogenization technique. First, the lipid components were melted and mixed at 60 °C 
and the drug was dispersed in the molten lipid mixture. Then water heated to 60 °C 
was poured into the molten lipid mixture and the two phases were homogenized at 
13,500 rpm for 1 min and then at 8,000 rpm for 3 min using an Ultra Turrax. Finally, 
the dispersion was cooled to room temperature to solidify the lipid phase and obtain 
the lipid nanoparticles. 
 
2.2.1.4. Microparticles 
Ethyl cellulose microparticles were prepared by the solvent evaporation method. The 
polymer was dissolved in ethyl acetate and the polymer solution was emulsified in 
30 ml aqueous surfactant solution via high shear homogenization using an Ultra Turrax 
at 8,000 rpm for 10 s and then at 9,500 rpm for 20 s. The ethyl acetate was removed 
by continuous stirring of the dispersion overnight under a fume hood and the remaining 
organic solvent was removed at 40 °C using a rotary evaporator. The microparticles 
were collected by filtration through a 0.45 µm cellulose nitrate filter (Whatman® GE 
Healthcare UK Ltd., Buckinghamshire, UK) and dried under a fume hood. 
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2.2.2. Drying of nanoparticle suspensions 
After preparation, whenever necessary, the nanoparticle suspensions were freeze 
dried or spray dried. 
 
2.2.2.1. Freeze drying 
The nanoparticle suspension was shock frozen with liquid nitrogen and subsequently 
freeze dried (Alfa® 2-4 LD Plus freeze-dryer, Martin Christ Gefriertrocknungsanlagen 
GmbH, Osterode am Harz, Germany). Freeze-drying was performed at −47 °C and 
0.055 mbar.  
 
2.2.2.2. Spray drying 
The nanoparticle suspension was subsequently spray dried (Buechi 190 mini spray-
dryer; BUECHI, Flawil, Switzerland) using the following conditions: inlet 
temperature 120 °C; pump flow 6 g/min; spray flow 600 nl/h, aspirator pressure 
40 mbar; outlet temperature 80 °C.  
 
2.2.3. Artificial sebum preparation 
The lipid mixture of artificial sebum consisted of 15% squalene, 10% paraffin 
(solidification point 57-60 °C), 15% cetyl palmitate, 10% olive oil, 25% cotton seed oil, 
12% coconut oil, 6% oleic acid, 6% palmitic acid and 1% cholesterol (all by weight). 
The lipid components were mixed and heated to 60 °C to form a transparent lipid melt. 
Upon slow cooling of the transparent lipid mixture at ambient temperature, a 
homogeneous semi-solid mass was obtained. The artificial sebum contains the typical 
quantities of lipids in human sebum (Lu et al., 2009) based on commercially available 
materials.  
 
2.2.4. Measurement of the particle size and zeta potential of nanoparticles 
The particle size, polydispersity index (PDI) and zeta potential of the nanoparticles 
were measured at 25 °C by dynamic light scattering (Zetasizer® Nano ZS, Malvern 
Instruments Ltd., Malvern, UK). Prior to the measurement the samples were diluted to 
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0.1% (w/v) polymer with Milli-Q water to measure the particle size and with conductivity 
adjusted Milli-Q water (50 µS/cm) to measure the zeta potential. 
 
2.2.5. Measurement of the particle size of microparticles 
The particle size of microparticles was measured by laser diffractometry (Mastersizer® 
2000, Malvern Instruments Ltd., Malvern, UK). The dispersion medium was purified 
water. The obscuration was adjusted from 4 to 6%. Stirring speed was set to 750 rpm 
and no sonication was used. As characteristic parameters the d0.1, d0.5 and d0.9 were 
obtained. 
 
2.2.6. Determination of encapsulation efficiency, loading capacity and yield 
The total drug amount in the nanocrystal and polymeric nanoparticle suspensions were 
determined spectrophotometrically (Agilent HP 8453, Agilent Technologies Inc., Santa 
Clara, US) at 242 nm after dissolving the nanoparticles in water and 60% (w/w) 
isopropanol, respectively. In the case of Eudragit® RS nanoparticles and ethyl 
cellulose/Eudragit® RS nanoparticles quantification was conducted at 260 nm due to 
UV absorption by Eudragit® RS at 242 nm. During spectrometric measurements drug 
free nanoparticles treated the same way were used as blank standards. The 
determination of the drug content of lipid nanoparticles was not necessary as the 
samples were not filtered.  
The encapsulation efficiency and loading capacity of the nanocrystals, polymeric 
nanocarriers and lipid nanoparticles were determined indirectly by determining the 
amount of dexamethasone dissolved in the aqueous phase.  
The separation of the nanocrystals and polymeric nanoparticles from the external 
aqueous phase was done by centrifugation (HereausTM BiofugeTM StratosTM, Thermo 
Electron Corp., Osterode, Germany) of the colloidal dispersion at 17,000 rpm and 
23 °C for 8 h. The amount of drug in the aqueous phase was quantified 
spectrophotometrically at 242 nm. During spectrometric measurements drug free 
nanoparticles treated the same way were used as blank standards. 
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In case of lipid nanoparticles the continuous phase was separated from the lipid 
nanoparticles by centrifugation of the colloidal dispersion in a 10 kDa molecular weight 
cut-off (MWCO) filter (Vivaspin® 500, VWR International GmbH, Darmstadt, Germany) 
for 4 h at 15,000 g at 10 °C to avoid melting of the lipid phase during centrifugation. 
The amount of nanoparticle recovered after preparation and filtration was determined 
by freeze drying 2 ml of the aqueous nanosuspension.  
The percentage drug encapsulation efficiency (%EE) was calculated as (mass of total 
drug - mass of non-entrapped drug)/mass of total drug * 100%. The percentage drug 
loading capacity (%LC) was calculated as mass of entrapped drug/mass of 
nanoparticles recovered * 100%. The percentage yield was calculated as mass of 
nanoparticles recovered/theoretical mass * 100%. 
 
2.2.7. Redispersibility 
The redispersibility of the freeze-dried nanoparticles was investigated visually and by 
measuring the particle size of the nanoparticles after redispersing the dried 
nanoparticles in Milli-Q water. 
 
2.2.8. Microscopy 
2.2.8.1. Optical light microscopy and cross polarized light microscopy 
Microscopic and cross polarized light microscopic images were taken using a cross 
polarized light microscope (Zeiss Axioskop, Carl Zeiss Microscopy GmbH, Jena, 
Germany) equipped with an Axiocam 105 color camera and ZEN software (Carl Zeiss 
Microscopy GmbH, Jena, Germany). Furthermore, the microscope was equipped with 
a Mettler Toledo FP82HT hot stage (Mettler-Toledo GmbH, Giessen, Germany) to heat 
the sample if necessary. 
 
2.2.8.2. Confocal laser scanning microscopy (CLSM) 
Histological sections of porcine ear skin containing hair follicles, obtained after follicular 
penetration experiments, were examined under a CLSM (LSM 700, Carl Zeiss, Jena, 
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Germany) using a Plan-Apochromat 10×/0.45 M27 objective. The penetration of Nile 
red (at an excitation wavelength of 555 nm, laser intensity 2.0, pinhole 1 AU, Gain 600, 
digital offset 0, digital gain 1.0 and emission wavelengths of 590 nm) was tracked in 
the hair follicles. Skin samples without nanoparticle suspensions were used as 
negative controls for configuration of the microscope settings. 
The accumulated fluorescence intensity of Nile red in hair follicles was determined with 
ImageJ software. The area in each hair follicle was sectioned from image of the 
fluorescence channel, and then the marked area was analyzed by imageJ. The value 
of the sum of the values of the pixels was taken as the accumulated fluorescence 
intensity of Nile red in hair follicle.  
 
2.2.9. Determination of solubilities and partition coefficients 
2.2.9.1. Dexamethasone solubility in aqueous media 
An excessive amount of dexamethasone was added to the investigated aqueous 
media and stirred at 600 rpm for 3 days. Afterwards the suspension was centrifuged 
at 17,000 rpm and 23 °C for 8 h. The amount of drug in the supernatant was quantified 
spectrophotometrically at 242 nm. 
 
2.2.9.2. Dexamethasone solubility in artificial sebum and paraffin 
The dexamethasone solubility in artificial sebum and paraffin was determined half 
quantitatively. Therefore, various dexamethasone amounts (0.005%, 0.01%, 0.02%, 
0.05% and 0.1% w/w) were added to artificial sebum and liquid paraffin, respectively. 
Afterward the dexamethasone artificial sebum and dexamethasone liquid paraffin 
mixtures were placed in an oven (T6120, Heraeus Instruments, Osterode, Germany) 
at 60 °C and stirred at 600 rpm. After 24 h the dexamethasone artificial sebum and 
dexamethasone liquid paraffin mixtures were investigated visually if dexamethasone 
was dissolved. 
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2.2.9.3. Dexamethasone solubility in polymer films. 
Polymer films with various drug to polymer ratios (1:20, 1:10, 1:5 and 1:2) were 
prepared to estimate drug solubility in pure polymer. The polymer and the drug were 
dissolved in acetone (5% w/w) and a thin film of the organic drug-polymer solution was 
casted on a microscopic slide. The organic solvent was evaporated under a fume hood 
and the remaining solvent was removed in a vacuum oven (HeraeusTM VT 5042 EK, 
Thermo Electron Corp., Osterode, Germany) at room temperature for 2 h. The polymer 
films were observed visually for clarity and under a cross polarized light microscope 
for drug recrystallization. 
 
2.2.9.4. Polymer solubility in artificial sebum 
The solubility of different polymers in artificial sebum was determined half 
quantitatively. Therefore, various polymer amounts (0.1%, 0.5%, 1%, 2%, 5%, 10%, 
20% and 30% w/w) were added to artificial sebum and stirred at 600 rpm at 60 °C in 
an oven. After 24 h the artificial sebum polymer mixtures were investigated visually if 
the polymer was dissolved. 
 
2.2.9.5. Artificial sebum/water and paraffin/water partition coefficient of 
dexamethasone  
The artificial sebum/water and liquid paraffin/water partition coefficient of 
dexamethasone were determined indirectly by measuring the amount of 
dexamethasone dissolved in the aqueous phase. 4 ml of an aqueous 43.8 ± 0.3 µg/ml 
dexamethasone solution was added to 4 ml artificial sebum and respectively to 4 ml 
liquid paraffin, heated to 60 °C and mixed to form an emulsion. These emulsions were 
placed in an oven at 37 °C and stirred at 600 rpm for 24 h. Afterwards the emulsions 
were centrifuged at 17,000 rpm and 37 °C for 8 h. The amount of dexamethasone in 
the supernatant was quantified spectrophotometrically at 242 nm. During 
spectrometric measurements dexamethasone free water treated the same way was 
used as blank standard. The partition coefficients were calculated as dexamethasone 
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amount in water at the beginning – dexamethasone amount in water after 
24 h/dexamethasone amount in water after 24 h. 
 
2.2.10. Recrystallization of dexamethasone from saturated 
dexamethasone solutions 
1.8 ml saturated dexamethasone solution was put in a petri dish (d = 35 mm). The petri 
dish was placed in an oven at 32 °C and at predefined time points (1 h, 2 h, 4 h, 6 h, 8 
h and 24 h) the evaporated amount of water was determined by weight loss. Afterwards 
the remaining solution was observed under a cross polarized light microscope for drug 
recrystallization. 
 
2.2.11. Differential scanning calorimetry (DSC) measurements  
Thermograms of powders, artificial sebum and artificial sebum powder mixtures were 
recorded using a DSC 6000 (PerkinElmer, Inc.  Waltham, MA, USA).  Powders (5 – 
10 mg), artificial sebum (15 - 20 mg) and artificial sebum mixtures (15 - 20 mg) were 
weighed accurately in 50 µl aluminum pans with pierced lid. DSC scans were recorded 
for a heating, cooling, heating run at a heating rate of 10 ºC/min within 0 °C and 160 ºC 
and a cooling rate of 40 °C/min. The thermogram of the second heating run was 
recorded, because the glass transition temperature (Tg) of polymers determined in the 
first heating run is affected by the thermal history of the polymer. Heating polymers first 
above the Tg and then quench cooling, eliminate the thermal history of polymers 
(Grijpma and Pennings, 1994). The Tg was evaluated with the Pyris software 
(PerkinElmer, Inc.  Waltham, MA, USA). 
 
2.2.12. Viscosity measurements 
The viscosity and viscoelasticity of viscous and viscoelastic fluids were measured 
using a rheometer (MCR 302, Anton Paar, Graz, Austria). The viscosity was measured 
at varying shear rate (2 - 50 s-1) and the viscoelasticity was examined in oscillatory 
amplitude sweep measurements with a fixed angular frequency of 10 rad/s and at 
varying strain (0.1% - 100%). Aqueous nanosuspensions were measured with a double 
gap measuring system DG27 and gels, artificial sebum and artificial sebum powder 
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mixtures were measured with a cone plate measuring system CP25 TG. Aqueous 
nanosuspensions and gels were investigated at 25 °C and artificial sebum and artificial 
sebum powder mixtures were investigated at 37 °C. 
 
2.2.13. Erosion and dissolution behavior of microparticles in artificial 
sebum 
The swelling, erosion and dissolution behavior of 20% (w/w) of ethyl cellulose 
microparticles in artificial sebum was investigated under a microscope at 37 °C.  
 
2.2.14. In vitro drug release 
Drug release from the nanoparticles was investigated using three different in vitro 
release methods. Experiments were conducted under sink and non-sink conditions 
where the amount dexamethasone in the receiver compartment at 100% drug release 
equals 10% and 50% (w/v) of its saturation solubility, respectively. The saturation 
solubility of dexamethasone differed between the used dexamethasone batches. The 
dexamethasone batch used for the experiments in section 3.1 and section 3.2. had a 
saturation solubility of 66 ± 1 µg/ml in pH 7.4 phosphate buffer. The dexamethasone 
batch used for the experiments in section 3.3. Had a saturation solubility of 90 ± 1 
µg/ml in pH 7.4 phosphate buffer. 
 
2.2.14.1. In situ drug release investigations using Sirius® inForm 
The calculated amount of the nanoparticle dispersions was added manually into 40 ml 
release medium in an in situ release study apparatus (Sirius® inForm, Sirius Analytical 
Instruments Ltd., Forest Row, UK) which was maintained at 32 °C. The pH of the 
release medium was automatically adjusted to 7.4 and stirred at 100 rpm. The UV 
absorbance of the released dexamethasone was read between intervals using a 5 mm 
UV probe immersed in the release medium. Prior to the release experiment the 
molecular extinction coefficient of dexamethasone was determined, which was later 
used to automatically calculate the percentage of drug released as a function of time. 
Analysis of the results was preceded by simple background correction for nanocrystals 
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and Tyndall background corrections for lipid nanoparticles and polymeric nanoparticles 
to adjust for the effect of light lost due to scattering by the nanocarriers. 
 
2.2.14.2. Dialysis bags 
The calculated amount of the nanoparticle dispersion containing the required amount 
of dexamethasone was placed in a preconditioned dialysis bag (Float-A-Lyzer® G2, 
20 kDa MWCO, Spectrum Laboratories, Inc., CA, USA) and the bag was put in a 
container containing pH 7.4 phosphate buffer as a release medium. Then the whole 
set-up was placed in an incubation shaker which was maintained at 32 °C and 
continuously shaken at 120 rpm. 1 ml (under sink condition) or 0.4 ml of the sample 
(under non-sink condition) was withdrawn at predefined time intervals (1, 3, 7, 24 and 
48 h) and replaced by fresh release media. The released dexamethasone was 
quantified by a UV- spectrometer at 242 nm. 
 
2.2.14.3. Franz diffusion cells 
An appropriately conditioned regenerated cellulose membrane (Spectra/Por® 2 
Dialysis Membrane, RC discs of MWCO 12–14 kDa, Spectrum Laboratories, Inc., CA, 
USA) was mounted on a Franz diffusion cell, the acceptor compartment was filled with 
pH 7.4 phosphate buffer, and the whole diffusion cell was placed in a thermostatic 
bath, which was maintained at 32 °C. The calculated amount of the nanoparticle 
suspension was placed on the donor compartment and closed using a wax foil 
(Parafilm M®, Bemis Company Inc., Oshkosh, WI, USA) to prevent water evaporation. 
The acceptor compartment was stirred at 600 rpm throughout the release experiment 
and 0.4 ml sample was withdrawn at predefined time interval (0.25, 0.75, 1.5, 3, 5, 7 
and 24 h) and replaced by fresh buffer media. The released dexamethasone was 
quantified by a UV- spectrometer at 242 nm. 
Franz diffusion cell experiments to investigated sebum responsive drug release were 
optimized to investigate the responsive drug release. Drug release from the 
nanoparticles was investigated under non-sink condition (20 µg/ml, in the acceptor 
compartment at 100% drug release). Before mounting the membranes on the Franz 
diffusion cell, the membranes were soaked either in water, paraffin or artificial sebum 
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for 15 h at 37 °C. The temperature of the thermostatic bath during the experiment was 
change to 37 °C and the donor compartment was not closed with a wax foil to simulate 
the physiological conditions inside the hair follicle. The predefined time intervals were 
changed to 1, 2, 4, 6, 8 and 24 h. 
 
2.2.14.4. Determination of drug flux through the dissolution membrane 
Dexamethasone flux (µg/cm2h) through the dissolution membranes was measured by 
determining the slope of the linear part of the drug release curve at the initial stages of 
drug release. 
 
2.2.15. Ex vivo drug release and penetration studies with excised human 
skin 
The ex vivo skin drug penetration and release studies were performed in cooperation 
with the research groups of Prof. Dr. Sarah Hedtrich and PD Dr. med. Annika Vogt. 
Cutaneous absorption of dexamethasone was investigated using female human, 
abdominal skin with no damages, stretch marks or scars (obtained from plastic 
surgeries with permission and informed consent) in accordance with a validated 
protocol (OECD guideline no. 428 (2004a)). Immediately after surgical removal, the 
subcutaneous layer of the skin was removed, the skin was washed with PBS and kept 
in a freezer (- 20 °C). 
 
2.2.15.1. Franz diffusion cell 
During the experiment, the defrosted skin (< 6 months) was mounted on Franz diffusion 
cells and the formulations equivalent to 10 µg/cm2 dexamethasone were applied on 
the skin surface and were incubated at 32 °C for 6 h. The donor compartment was 
filled with PBS. Then the excess material loosely attached to the skin surface was 
carefully removed by tape-stripping twice. Epidermis and dermis were heat separated 
(1 min in 60 °C hot water) and the dermis was horizontally cut into 50 µm sections at 
- 24 °C using a freeze microtome (Frigocut 2800N, Leica Microsystems Holding GmbH, 
Bensheim, Germany). Epidermis and dermis skin slices were subjected to 5 freeze-
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thaw cycles. Following the addition of 50 pmol Dex-d4 as internal standard, samples 
were extracted 3 times with 500 µl ethyl acetate. Combined extracts were exsiccated 
by vacuum rotation and the dried residues were reconstituted in 200 ml acetonitrile. 
Dexamethasone concentrations in extracts of ex vivo human skin samples were 
quantified by LC-MS/MS as described previously (Döge et al., 2016). 
 
2.2.15.2. Microdialysis 
For microdialysis studies, the recesses in the device were filled with culture medium 
(KGM-Gold™ Keratinocyte Growth Medium, Lonza Group AG, Basel, Switzerland) and 
2.5 × 4 cm2 areas of intact skin were pinned, dermis side down, on the device. For 
topical administration of the dexamethasone formulations, a lid containing 9 holes 
(1 cm2) was screwed on top of the device with carefully positioning of each skin sample 
(3 donors) directly below a hole. 5 h after topical application, the lid of the device was 
removed and a microdialysis probe (Ep High Flux Probes 45 kDa MWCO, EP Medical 
ApS, Copenhagen, Denmark) was inserted in the emerged 1 cm2 skin using a guide 
canula (0.60 mm × 25 mm, 100 Sterican®, B. Braun Melsungen AG, Melsungen, 
Germany). The position was controlled by optical coherence tomography (VivoSight 
Michelson Diagnostics Ltd., Maidstone, UK). The canula was withdrawn leaving the 
fiber placed within the skin. Probes were perfused with PIPES buffer (pH 7.4) at a 
constant flow rate of 3 μl/min using a pump (Univentor 864 Syringe Pump, Univentor 
Limited, Zejtun, Malta). Microdialysis samples were collected manually at 6, 12 and 24 
h after topical application for a period of 1 h (time-intervals: 6 – 7 h, 12 – 13 h and 24 
– 25 h) at room temperature using a new probe for the last collection step. During the 
intervals, the skin was kept in an incubator. The amount of dexamethasone in 
microdialysis samples was quantified by LC-MS/MS as described previously (Döge et 
al., 2016). 
 
2.2.16. Ex vivo hair follicular penetration studies 
The ex vivo hair follicular penetration studies were performed in cooperation with the 
group of Prof. Dr. Dr.-Ing. Jürgen Lademann. For the ex vivo follicular penetration study 
fresh porcine ear skin from a local abattoir was used. The porcine ears were stored in 
the refrigerator for less than 3 days before use. The skin was thoroughly washed with 
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distilled water and dried with tissue paper afterwards. The hairs were trimmed using a 
pair of scissors and an adhesive solution was put around the application area (2 cm × 
2 cm) and dried for 90 min, to prevent lateral diffusion of the colloidal dispersion. Then 
80 µL of Nile red-loaded ethyl cellulose or Eudragit® RS nanoparticle suspension was 
uniformly spread over the application area and was massaged for 2 min using a mini 
massager (Rehaforum Medical GmbH, Elmshorn, Germany). Then the skin was 
incubated at 32 °C for 1 h. The Nile red-loading was 0.004% based on the polymer 
amount. Afterwards, cryo spray was used and biopsies of about 0.6 cm × 0.6 cm were 
cut out using a scalpel. The biopsies were put in an Eppendorf tube, frozen in liquid 
nitrogen and stored at −20 °C. Finally, the biopsies were mounted in a frozen tissue 
freezing medium and 10 µm histological sections containing hair follicles (n = 7) were 
cut out using a cryostat (Microm HM 560, Microm GmbH, Walldorf, Germany). The 
histological sections were observed under a CLSM to determine the penetration depth 
and fluorescence intensity of the dye. Approval to conduct the ex vivo experiments 
using the porcine ear skin was obtained from the Veterinaeramt Berlin. 
 
2.2.17. Toxicity study 
The toxicity studies were performed in cooperation with the research group of Prof. Dr. 
Burkhard Kleuser. 
 
2.2.17.1. Isolation and cultivation of primary human keratinocytes 
Primary human keratinocytes (NHK) were isolated from juvenile foreskins (with ethical 
consent). The cells were isolated and cultivated according to a standard protocol 
(Gysler et al., 1997). The NHK cells were grown in KGM supplemented with Bullet Kit 
at 37 °C in a humidified atmosphere with 5% CO2. The cells used in all the experiments 
did not exceed passage 4 and were seeded and maintained during experiments in 
KGM. 
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2.2.17.2. 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) 
assay 
The MTT assay is a widely used method to determine the viability in metabolic active 
cells. The assay was carried out as described previously (Kumar et al., 2014). It is 
based on the conversion of the yellow MTT to formazan blue by the mitochondrial 
reductase system. NHKs were seeded into 96-well plates (TPP AG, Trasadingen, 
Germany) with a density of 10,000 cells per well. After 24 h, the nanoparticles 
(prepared without dexamethasone) were added to the well plates forming a final 
concentration of 50 and 500 µg/ml and were further incubated for 24 h and 48 h. 
Subsequently, the cells were incubated with 100 µl MTT solution (0.5 mg/ml in PBS) 
for 4 h. After removing the supernatants, 50 µl dimethyl sulfoxide was added to dissolve 
the formazan salt and its optical density was measured using a microplate reader 
(Tecan AG, Crailsheim, Germany) setting the excitation to 540 nm. As a positive 
control 0.003% SDS was used. Untreated cells and the solvent control (1% w/v PVA 
solution) served as references. The measured absorbance values of the untreated 
cells were considered as 100% cell viability. A cell viability <80% predicts cytotoxic 
effects. 
 
2.2.17.3. 6-carboxy-2´,7´-dichlorodihydrofluorescein diacetate (H2DCFDA) assay 
Intracellular reactive oxygen species (ROS) levels were measured using the 
H2DCFDA assay. H2DCFDA is a chemically reduced, acetylated form of fluorescein 
used as an indicator for ROS in cells (Jaeger et al., 2012). This nonfluorescent 
molecule is deacetylated by intracellular esterases and can be oxidized by radicals 
such as hydroxyl, peroxyl, alkoxyl, nitrate and carbonate to a fluorescent molecule 
(excitation 495 nm, emission 525 nm). NHKs were seeded in 12-well plates (100,000 
cells per well) and grown for 24 h (37 °C, 5% CO2) in KGM supplemented with Bullet 
Kit. Then cells were incubated with 50 and 500 µg/ml nanoparticles (prepared without 
dexamethasone) for 1 h in KGM. After exposure, cells were loaded with 25 µM 
H2DCFDA in the same media for 1 h at 37 °C. The cells were harvested by trypsin 
incubation and collected in 2 ml reaction tubes. Thereafter, cell pellets were washed 5 
times with ice-cold FACS buffer. After resuspending the cell pellet in 200 ml FACS 
buffer, the samples were analyzed by FACSCanto II (BD Biosciences, Heidelberg, 
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Germany). The H2DCFDA fluorophor was measured in the fluorescein isothiocyanate 
(FITC) channel (488 nm excitation). Silver nanoparticles (40 nm) served as positive 
control. Untreated cells and the solvent control served as references. Fluorescence 
was measured in 10,000 cells and the mean value of the fluorescence was examined. 
The results are presented as mean fluorescence intensity (MFI). 
 
2.2.18. Statistical analysis 
Unless otherwise stated all measurements were conducted in triplicates and the data 
were given as mean ± standard deviation (SD). One-way ANOVA with Tukey test was 
performed to compare means at the statistical significance level (P) ≤ 0.05. Drug 
release profiles were compared by using two-way ANOVA followed by the Tukey test 
at p ≤ 0.05. 
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3. Results and discussion 
 
List of contributions from other research scientists (research groups): 
Nanoparticles provided by other research scientists: 
Nanocrystals provided and characterized by Miriam Colombo (Table 7, Figure 32-39 
and Figure 41). 
Lipid nanoparticles provided and characterized by Gaith Zoubari (Table 7, Figure 33 
and Figure 35-38). 
Experiments performed by other research scientists (research groups): 
In situ drug release investigations using Sirius® inForm performed by Miriam Colombo 
(Figure 33-34). 
Ex vivo drug release and penetration study performed by Stefan Hönzke (research 
group of Prof. Dr. Sarah Hedtrich) (Figure 15 and Figure 41). 
Intradermal micro dialysis experiments using excised human skin performed by Nadine 
Döge (research group of Dr. Annika Vogt) (Figure 41). 
Ex vivo follicular penetration study performed by Pin Dong (research group of Prof. Dr. 
Jürgen Lademann) (Figure 30-31). 
MTT and H2DCFDA assay performed by Dr. Christian Gerecke (research group of 
Prof. Dr. Burkhard Kleuser) (Figure 16-17). 
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3.1. Part I: Preparation and optimization of polymeric 
nanoparticles with controlled drug release3 
Corticosteroids are commonly used for the treatment of inflammatory skin diseases. 
However, treatment effectiveness using corticosteroids is highly dependent on drug 
release at the application site because high drug concentration often leads to serious 
local and systemic side effects like skin atrophy (Schoepe et al., 2006).  
Therefore, nanoparticles that adhere and penetrated to/into the skin and release the 
drug in a controlled manner may significantly reduce local and systemic side effects 
associated with corticosteroid therapy and improve treatment effectiveness and patient 
compliance.  
Nanoparticles offer a number of advantages for dermal drug delivery, including 
improved drug solubility and stability, adjustable surface properties, increased surface 
adhesion, drug targeting, controlled drug release and increased drug penetration and 
permeation through the skin (Kesisoglou et al., 2007; Küchler et al., 2009b; Merisko-
Liversidge et al., 2003; Sahle et al., 2016; Schafer-Korting et al., 2007; Shim et al., 
2004). Nanoparticles penetrate deep into a barrier-disrupted skin, whereas a healthy 
skin restricts the penetration of the nanoparticles, thus, minimizing side effects (Abdel-
Mottaleb et al., 2012; Contri et al., 2016; Kimura et al., 2012; Zhang and Monteiro-
Riviere, 2008). Moreover, delayed drug release from the nanoparticles allows better 
localization of the drug in the epidermis with low skin permeation tendency (Abdel-
Mottaleb et al., 2011).  Nanoparticles can also penetrate deep into the hair follicles and 
stay there for several days to release the drug slowly (Lademann et al., 2015). The 
follicular route might also be used to target dendritic cells and other cells that are 
involved in inflammatory processes (Lademann et al., 2005; Vogt et al., 2005). 
Nanoparticle surface charge has a significant effect on adhesion and penetration of 
nanoparticles through the skin (Contri et al., 2016; Wu et al., 2010). The skin is 
negatively charged under normal physiological conditions (Marro et al., 2001; 
                                            
3 Parts of this chapter were taken from: B. Balzus, F.F. Sahle, S. Hönzke, C. Gerecke, F. Schumacher, 
S. Hedtrich, B. Kleuser, R. Bodmeier, Formulation and ex vivo evaluation of polymeric nanoparticles for 
controlled delivery of corticosteroids to the skin and the corneal epithelium, Eur. J. Pharm. Biopharm., 
115 (2017) 122-130. 
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Rojanasakul and Robinson, 1989) and positively charged nanoparticles may adhere. 
Cationic amino-functionalized polystyrene and Eudragit® RS nanoparticles penetrated 
deeper into the skin in comparison to negatively charged nanoparticles. This is 
attributed to lack of electrostatic interaction with negatively charged nanoparticles that 
impaired access to the outermost skin layer (Contri et al., 2016; Wu et al., 2010). 
Different polymers with different solubility, polarity, biocompatibility, biodegradability, 
swelling and charge can be used for the preparation of polymeric nanoparticles. 
Eudragits and cellulose derivates are among the most commonly used polymers. 
Eudragits are copolymers of methacrylic acid and methacrylic/acrylic esters or their 
derivatives, which include neutral, cationic and anionic polymers. Eudragit® RS is a 
positively charged, water-insoluble copolymer of ethyl acrylate, methyl methacrylate 
and a low content of a methacrylic acid ester with quaternary ammonium groups. It is 
commonly used in controlled drug delivery systems (Thakral et al., 2013). In dermal 
drug delivery, Eudragit® RS nanoparticle-based heparin gels controlled drug release 
into the stratum corneum in comparison to a heparin solution (Loira-Pastoriza et al., 
2012). Capsaicinoids-loaded Eudragit® RS nanoparticles embedded into chitosan gels 
increased skin adhesion and drug penetration in contrast to a capsaicinoids chitosan 
gel (Contri et al., 2014). Cellulose-based polymers are also commonly used to prepare 
controlled release drug delivery systems. Ethyl cellulose is a water insoluble polymer 
and is commonly used for the preparation of controlled drug delivery systems (Rekhi 
and Jambhekar, 1995). Quercitin-loaded ethyl cellulose nanoparticles controlled the 
drug release with increased quercitin skin retention (Sahu et al., 2013).  
The objective of this study was to prepare dexamethasone-loaded Eudragit® RS and 
ethyl cellulose nanoparticles, which can adhere well to the skin or penetrate into the 
hair follicle to release the drug slowly and in a controlled manner to minimize 
corticosteroids therapy associated side effects and improve patient compliance and 
treatment effectiveness.  
 
3.1.1. Nanoparticle preparation and characterization 
Nanoparticles were prepared by the solvent evaporation method with ethyl acetate a 
class 3 residual solvent (ICH Q3C(R6) guideline). Different ethyl cellulose- and 
Eudragit® RS-based polymeric nanoparticles were formulated with different surfactants 
for controlled delivery of dexamethasone into the skin. The two polymers and 
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surfactants differ in their physicochemical properties, e.g. chemical structure, charge 
and hydrophobicity and are stable in aqueous formulations (Rekhi and Jambhekar, 
1995; Thakral et al., 2013). Therefore, nanoparticles with different properties and drug 
release profiles were expected. 
 
3.1.1.1. Nanoparticle preparation with different surfactants – Effect on particle 
size, PDI and encapsulation efficiency 
To prepare stable aqueous formulations of dexamethasone-loaded ethyl cellulose 
nanoparticles the following surfactants were screened PVA, poloxamer 188, 
poloxamer 407, Tween® 80, CTAB and sodium deoxycholate. Furthermore the effect 
of the different surfactants on the particle size, PDI and encapsulation efficiency of the 
nanoparticles was investigated.  
First, the dexamethasone solubility in different surfactants was determined (Table 1).  








- (water) - 66 ± 1 
PVA no data 115 ± 1 
Poloxamer 188 0.1%  
(Saski and Shah, 1965) 
88 ± 2 
Poloxamer 407 0.7%  
(Guzmán et al., 2007) 
100 ± 4 
Tween® 80 0.0013%  
(Katakam et al., 1995) 
320 ± 7 
CTAB  0.083%  
(Haque et al., 1999) 
6378 ± 61 
Sodium deoxycholate 0.032%  
(Chattopadhyay and London, 1984) 
338 ± 7 
2.5% (w/v) aqueous PVA, poloxamer 188 and 407 solutions exhibited the lowest 
dexamethasone solubility, whereas the dexamethasone solubility in 2.5% (w/v) 
aqueous Tween® 80 and sodium deoxycholate solutions was already ~5 times 
increased compared to the dexamethasone solubility in water. The dexamethasone 
solubility in 2.5% (w/v) aqueous CTAB solution was highly increased. CTAB was 
excluded from further studies for the nanoparticle preparation, because due to its high 
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solubilizing capacity of dexamethasone in the external aqueous phase a low 
encapsulation efficiency was expected.   
There was no considerable effect on the particle size observed for dexamethasone-
loaded ethyl cellulose nanoparticles in different surfactant solutions. All prepared 
nanoparticles were in a size range of ~170 – 220 nm (Table 2).  
Table 2: Size, PDI and encapsulation efficiency of aqueous nanosuspensions prepared with 5% (w/w) 
ethyl cellulose nanoparticles, 0.1% (w/w) dexamethasone and 2.5% (w/v) of different surfactants. 
Dexamethasone-loaded ethyl cellulose nanoparticles 
Surfactant  Size (nm) PDI Encapsulation 
efficiency (%) 
PVA 168 0.118 88.7 
Poloxamer 188 171 0.194 76.1 
Poloxamer 407 190 0.191 82.7 
Tween® 80 195 0.243 55.8 
Sodium deoxycholate 215 0.349 53.9 
However, the PDI was affected by the choice of surfactant. Thus ethyl cellulose 
nanoparticles prepared with sodium deoxycholate had a PDI above the limit value of 
0.25 for a narrow particle distribution (Tantra et al., 2010) , while formulations with the 
other surfactants had a PDI below 0.25. The nanoparticle size distribution ranking from 
broad to narrow with different surfactant was the following: deoxycholate, Tween® 80, 
poloxamer 188, poloxamer 407 and PVA.  The encapsulation efficiency of the 
dexamethasone-loaded ethyl cellulose nanoparticles prepared with sodium 
deoxycholate and Tween® 80 was lower than the encapsulation efficiency of the ethyl 
cellulose nanoparticles prepared with PVA, poloxamer 188 and poloxamer 407 (Table 
2). This observation was in accordance with the higher dexamethasone solubility in the 
surfactant solutions of sodium deoxycholate and Tween® 80 which increased the non-
encapsulated solubilized drug in the external aqueous phase and thus decreased the 
encapsulation efficiency, compared to the surfactant solutions of PVA, poloxamer 188 
and poloxamer 407.  
In conclusion, according to the evaluated parameters PVA was considered the best 
surfactant among studied ones for the preparation of dexamethasone-loaded ethyl 
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cellulose nanoparticles. Nanoparticles in aqueous PVA solution had the smallest size 
and PDI and the highest encapsulation efficiency. 
However, all surfactants were screened at a surfactant to ethyl cellulose ratio of 1:2, 
which might be not the optimal for all surfactants. Therefore, a smaller particle size, 
PDI and higher encapsulation efficiency values might be possible to achieve by 
optimizing the surfactant concentration for each formulation. 
 
3.1.1.2. Effect of surfactants on the recrystallization of dexamethasone from 
saturated dexamethasone solutions 
The stability of aqueous nanosuspension after application to the skin is a critical 
practical aspect, which needs to be considered during formulation development. The 
evaporation of volatile components results in a rapid concentration increase of the 
remaining formulation components. This concentration effect could lead to 
destabilization/agglomeration of the nanoparticles and the formation of supersaturated 
drug solutions with a potential drug recrystallization in larger microcrystals (Coldman 
et al., 1969). Therefore, the effect of different surfactants, namely PVA, poloxamer 188, 
poloxamer 407, Tween® 80, CTAB and sodium deoxycholate on the recrystallization 
of dexamethasone in saturated dexamethasone solutions during evaporation of the 
aqueous phase was investigated (Figure 10). Saturated solutions were used instead 
of a fixed dexamethasone concentration, because the nucleation time depends on the 
degree of saturation (Raghavan et al., 2001). All surfactants were used as 2.5% (w/v) 
aqueous solution except CTAB, because the solubility of dexamethasone was highly 
increased in an aqueous 2.5% (w/v) CTAB solution (Table 1). Instead, an aqueous 
0.025% (w/v) CTAB solution had a dexamethasone saturation solubility of 82 ± 1 µg/ml, 
which was comparable to the dexamethasone solubility in water. Therefore, 0.025% 
(w/v) CTAB was screened as additive to inhibit the dexamethasone recrystallization 
during evaporation of the aqueous phase by its strong dexamethasone solubilization. 
An aqueous saturated dexamethasone solution served as a control. 




Figure 10: Aqueous saturated dexamethasone solutions without surfactant, with 0.025% (w/v) CTAB, 
2.5% (w/v) PVA, poloxamer 188, poloxamer 407, Tween® 80 or sodium deoxycholate after evaporation 
of certain amounts of water % (w/w), arrow indicates crystal, scale bar 50 µm. 
3. Results and discussion 
58 
 
For saturated dexamethasone solution without surfactant crystals were observed when 
60.8% of the aqueous phase was evaporated. In formulation with Tween® 80 no 
crystals were visible until 78.8% water loss. In case of sodium deoxycholate the first 
crystals appeared after 42.6% water loss however after evaporation of the complete 
aqueous phase no crystals were visible anymore. In formulations with CTAB, PVA, 
poloxamer 188 and poloxamer 407 crystals could be observed already after 12.7% 
water loss. (Table 3). Poloxamer 407 formed a film after complete water evaporation, 
which was shiny under the polarized light microscope (Figure 10). Due to this 
phenomenon dexamethasone recrystallization could not be investigated in the 
poloxamer 407 film by polarized light microscopy.  
Table 3: : Saturated dexamethasone solutions without surfactant, with 0.025% (w/v) CTAB, 2.5% (w/v) 
PVA, poloxamer 188, poloxamer 407, Tween® 80 or sodium deoxycholate after evaporation of certain 



















12.7 ± 1.0 - Crystals Crystals Crystals - - Crystals 
22.7 ± 1.4 - Crystals Crystals Crystals - - Crystals 
42.6 ± 2.7 - Crystals Crystals Crystals - Crystals Crystals 
60.8 ± 3.0 Big crystals 
(50 µm) 
Crystals Big crystals 
(10 µm) 
Crystals - Crystals Crystals 
78.8 ± 3.9 Big crystals 
(50 µm) 
Crystals Big crystals 
(10 µm) 
Crystals - Crystals Crystals 
99.9 ± 0.1 Big crystals 
(100 µm) 
Crystals Big crystals 
(20-50 µm) 
Crystals Crystals - Crystals 
Surfactants were reported to inhibit or promote crystal growth (Raghavan et al., 2001; 
Rodriguez-Hornedo and Murphy, 2004). However, in all cases except Tween® 80, 
surfactants promoted the crystal growth since crystals appeared earlier than in the 
saturated dexamethasone solution without surfactants. This could be explained by the 
solubilization of drug molecules inside micelles and thereby concentrating the solute 
molecules (Garti and Zour, 1997). Furthermore, surfactants reduce interfacial surface 
tension what led to the decrease in the activation energy for crystal nucleation 
(Christoffersen et al., 1991). All surfactants were used at concentrations above their 
critical micelle concentration (Table 1), except CTAB, therefore both, drug 
solubilization in micelles and reduction of activation energy for nucleation could be 
valid explanation of the promotion of crystal growth.  
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Although, sodium deoxycholate induced crystal nucleation less than PVA, poloxamer 
188, poloxamer 407 and CTAB it could not inhibit nucleation as well as Tween® 80 did. 
It has been reported that the recrystallization inhibition is dependent on the drug-
surfactant interactions and as a result the selection of crystallization inhibitors is usually 
drug specific (Margulis-Goshen et al., 2011).  
The size and shape of the crystals formed during the evaporation study differed 
between the different surfactants (Figure 10). Crystals in aqueous saturated 
dexamethasone solution without surfactant and with poloxamer 188 had a prismatic 
shape and were bigger in size compared to the other surfactants. Crystals in an 
aqueous saturated dexamethasone Tween® 80 solution were needle shaped. The 
other surfactants led to small crystals, hence the shape could not be analyzed under 
light microscope.  
Differences in crystal size were related to differences in nucleation and crystal growth 
rates (Rodriguez-Hornedo and Murphy, 2004). When nucleation rate was faster than 
the crystal growth rate small crystals were formed whereas big crystals were formed 
when crystal growth rate was faster than the nucleation rate (Li et al., 2012).  Therefore, 
polymers inhibited the interaction of drug molecules and thus prevented crystal growth. 
Long needle shaped crystals as in the case of Tween® 80 indicated in some cases a 
high degree of supersaturation with a fast recrystallization (Boistelle and Astier, 1988; 
Rodriguez-Hornedo and Murphy, 2004) what is consistent with the best 
recrystallization inhibition by Tween® 80 due to its capacity to maintain the highest 
supersaturation degree of dexamethasone. 
The ethyl cellulose nanosuspensions (Table 2) were also studied regarding the 
recrystallization of dexamethasone. However, recrystallization could not be 
investigated during the evaporation due to the high light scattering caused by the 
dispersed nanoparticles, which significantly reduced the light intensity of the 
microscope. 
 
3.1.1.3. Dexamethasone solubility in ethyl cellulose and Eudragit® RS films 
Prior to drug loading, the dexamethasone solubility in ethyl cellulose, Eudragit® RS and 
ethyl cellulose/Eudragit® RS blends was estimated by a film casting method. Films 
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prepared with individual polymers appeared clear but films of polymer blends were 
hazy at all ratios investigated (3:1, 1:1 and 1:3) even in the absence of dexamethasone 
(Figure 11a-c). This might be attributed to polymer aggregation because of non-
specific polymeric interactions. Besides, in all cases, dexamethasone recrystallized at 
drug to polymer ratios of ≥1:5 (Figure 11d-f). 
 
Figure 11: Films of ethyl cellulose/Eudragit® RS blends without dexamethasone (a) 3:1, (b) 1:1 and (c) 
1:3 and films of (d) ethyl cellulose, (e) ethyl cellulose/Eudragit® RS (1:1) and (f) Eudragit® RS with a 
drug to polymer ratio of 1:5. 
 
3.1.1.4. Optimization of ethyl cellulose and Eudragit® RS nanoparticles 
Ethyl cellulose nanoparticles were larger than Eudragit® RS nanoparticles (Table 4). 
This can be attributed to the permanent positive charge at the surface of Eudragit® RS, 
which minimizes the tendency of nanoparticle-nanoparticle aggregation, and to the 
lower viscosity of the organic solution of Eudragit® RS (1.53 ± 0.04 mPa s) when 
compared to ethyl cellulose (9.56 ± 0.66 mPa s). Eudragit® RS exhibits a self-stabilizing 
effect (Bodmeier et al., 1991). Ethyl cellulose nanoparticles had a negative zeta 
potential due to adsorption of hydroxyl ions (Jin et al., 2012), whereas Eudragit® RS 
nanoparticles had a positive zeta potential due to the quaternary ammonium groups 
on the polymer surface. Ethyl cellulose nanoparticles also had higher dexamethasone 
encapsulation efficiency and loading capacity than Eudragit® RS nanoparticles, which 
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can be attributed to the higher hydrophilicity and surface charge of the Eudragit® RS 
which will led to a lower affinity towards the lipophilic dexamethasone. 
Table 4: Compositions and characteristics of dexamethasone-loaded polymeric nanoparticles 






























Size (nm); (PDI) 
NP-1 1:0 1 1:20 1:3 -18 54.9 1.4 96.6 120 0.074 NR 
NP-2 1:0 2 1:20 1:3 -21 47.8 1.7 93.2 125 0.088 NR 
NP-3 1:0 5 1:100 1:3 -36 87.0 0.8 95.1 172 0.150 NR 
NP-4 1:0 2 1:20 1:2 -21 66.4 2.2 97.4 139 0.058 NR 
NP-5 1:0 2 1:40 1:3 -22 72.3 1.2 97.4 124 0.082 NR 
NP-6 0:1 1 1:20 1:3 32 12.7 0.3 101.0 64 0.201 64; (0.199) 
NP-7 0:1 2 1:20 1:3 35 14.1 0.5 95.5 70 0.191 70; (0.196) 
NP-8 0:1 5 1:20 1:3 44 16.1 0.7 94.3 94 0.214 95; (0.216) 
NP-9 0:1 2 1:20 1:4 36 14.4 0.5 95.5 64 0.218 64; (0.209) 
NP-10 0:1 2 1:20 1:2 33 14.9 0.5 94.9 78 0.182 80; (0.174) 
NP-11 0:1 5 1:100 1:3 41 71.1 0.6 94.1 90 0.214 91; (0.203) 
NP-12 1:1 2 1:40 1:3 34 67.0 1.1 97.4 102 0.110 105; (0.110) 
* Percentage based on the aqueous phase; NR = not redispersible. The relative standard deviation 
(RSD, %) of the particle size, PDI, zeta potential, encapsulation efficiency, loading capacity and yield 
were 0.1 - 1.3, 0.5 - 27.4, 0.5 - 7.8, 0.1 - 1.3, 0.1 - 1.3 and 0.01 - 3.75, respectively. At a drug to polymer 
ratio of 1:20, dexamethasone was not completely soluble in 5% ethyl cellulose or 2% ethyl cellulose with 
an organic to aqueous phase ratio of 1:4. 
Generally, particle size, zeta potential, encapsulation efficiency and loading capacity 
of the polymeric nanoparticles increased with increasing polymer concentration and 
organic phase ratio (Table 4). The size increase can be attributed to a higher polymer 
concentration in the organic phase droplets or to the larger organic phase droplets in 
the emulsion. Increasing the polymer amount increased the zeta potential because 
less PVA is covering the nanoparticle surface and shielding the charge of the polymer. 
At high organic phase ratio, the rate of organic solvent evaporation with respect to the 
total organic phase is slower so that the solvent/drug flux out of the solvent/polymer 
droplet is reduced improving drug loading and entrapment. However, the changes 
were not considerable. 
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Nanoparticle size decreased slightly with increasing PVA concentrations (Figure 12), 
owing to the stabilizing effect of the surfactant. Eudragit® RS nanoparticles could be 
prepared without PVA because of the self-stabilizing effect of the polymer.  
 
Figure 12: Effect of PVA concentration on the particle size, zeta potential, entrapment efficiency and 
loading capacity of ethyl cellulose and Eudragit® RS nanoparticles. 
As expected, the absolute value of the zeta potential slightly decreased with increasing 
PVA concentration, because PVA is covering the nanoparticle surface and shielding 
the charge on the nanoparticle surface. PVA concentration had no significant effect on 
the encapsulation efficiency whereas the loading capacity decreased with increasing 
PVA concentration. This can be attributed to the drug solubilizing effect of PVA. 
As expected, the size of the ethyl cellulose/Eudragit® RS nanoparticles increased with 
increasing the ratio of ethyl cellulose (Figure 13). By increasing the percentage of ethyl 
cellulose in the ethyl cellulose/Eudragit® RS nanoparticles, the encapsulation efficiency 
and loading capacity increased significantly. At 75% (w/w) ethyl cellulose, there was 
partial nanoparticle aggregation (yield = 52.9%) and resulted in reduced drug 
encapsulation efficiency and loading capacity. In addition, the polymer ratio showed 
no significant effect on zeta potential and at all ratios investigated the ethyl 
3. Results and discussion 
63 
 
cellulose/Eudragit® RS nanoparticles had a positive zeta potential due to the 
permanent positive charge of the quaternary ammonium groups of Eudragit® RS. 
 
Figure 13: Effect of percentage ethyl cellulose in ethyl cellulose/Eudragit® RS nanoparticles on particle 
size, zeta potential, entrapment efficiency and loading capacity. 
Eudragit® RS and ethyl cellulose/Eudragit® RS nanoparticles were redispersible due 
to the self-stabilizing and hydrophilic character of Eudragit® RS because of their 
quaternary ammonium functional groups. However, ethyl cellulose nanoparticles were 
not redispersible (Table 4) because of their poor wettability (Schmidt and Bodmeier, 
1999). 
 
3.1.2. In vitro drug release 
Dexamethasone release from 2% ethyl cellulose, 2% Eudragit® RS and 2% ethyl 
cellulose/Eudragit® RS (1:3, 1:1, 3:1) nanoparticles, prepared at drug to polymer ratio 
of 1:20, was investigated in vitro (Figure 14a).  




Figure 14: Effect of (a) ethyl cellulose to Eudragit® RS ratio and (b) polymer amount in the 
nanosuspension on dexamethasone release. 
There was no significant difference in drug release between ethyl cellulose, Eudragit® 
RS and the ethyl cellulose/Eudragit® RS (3:1) nanoparticles. However, ethyl 
cellulose/Eudragit® RS (1:1 and 1:3) nanoparticles led to a faster drug release. 
Fast release of the hydrophobic dexamethasone is expected from hydrophilic 
Eudragit® RS nanoparticles. However, its low drug loading (0.5%) compared to ethyl 
cellulose nanoparticles (1.7%) might slow down the release and, hence, it had drug 
release comparable to ethyl cellulose nanoparticles. Upon blending the two polymers, 
a proportional change in polymer hydrophilicity and drug loading capacity was 
expected and there might have been no significant changes in drug release. However, 
the two polymers are not soluble in each other (Figure 11a-c) and when mixed at 1:1 
the more heterogeneous mixture was obtained. This might result in a porous matrix 
with an increased drug loading capacity and fast drug release. 
Interestingly, drug release decreased considerably with decreasing drug to polymer 
ratio (which was achieved by increasing the amount of the polymer in the dispersed 
phase to keep the amount of suspension applied in the donor phase constant) (Figure 
14b). This is expected because there is a high degree of drug encapsulation and 
probable formation of a high tortuous path. It is thus possible to control drug release 
by choosing the appropriate amount of the polymer within the nanosuspension. 
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3.1.3. Ex vivo drug release and penetration 
The ex vivo drug release and penetration experiments with excised human skin were 
performed in cooperation with the research group of Prof. Dr. Sarah Hedtrich. 
Drug release from nanoparticles into the skin is a complex process. Nanoparticle 
adhesion to and penetration into the outer layer of the skin lead to a longer retention 
time of the nanoparticles, where the drug can be released deeper and over a longer 
period of time. 
Dexamethasone release and penetration from 2% ethyl cellulose, 5% Eudragit® RS 
and 2% ethyl cellulose/Eudragit® RS (1:1) nanoparticles (Table 4) and a marketed 
cream, each loaded with 0.05% dexamethasone, were investigated ex vivo using 
excised human skin (Figure 15).  
 
Figure 15: Amount of dexamethasone in epidermis and dermis recovered 6 h after topical application of 
0.05% dexamethasone-loaded ethyl cellulose, Eudragit® RS and ethyl cellulose/Eudragit® RS (1:1) 
nanoparticles and DEXAMETHASON Creme LAW; 0,05%. 
In all the cases, over 6 h, an insignificant amount of dexamethasone was recovered in 
the acceptor compartment. More dexamethasone was recovered on the epidermis, 
with lesser degree of penetration into deeper layers, with ethyl cellulose nanoparticles 
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than the commercial cream. This can be attributed to slow release of dexamethasone 
from the nanoparticles. Dexamethasone release and penetration into the deeper layers 
increased when Eudragit® RS was blended with ethyl cellulose. This is in line with the 
results of the release study where drug release from ethyl cellulose/Eudragit® RS (1:1) 
nanoparticles was significantly faster than the pure polymers (Figure 14a). The ethyl 
cellulose/Eudragit® RS nanoparticles were also positively charged, which also have 
high tendency to adhere and penetrate through the skin than negatively charged or 
neutral nanoparticles (Wu et al., 2010). Thus, the increase in degree of drug 
penetration might be attributed to the charge and improved dexamethasone release 
from the ethyl cellulose/Eudragit® RS nanoparticles. Interestingly, dexamethasone 
penetration in both epidermis and dermis was lower from 5% Eudragit® RS 
nanoparticles (Figure 15). At high percentage of the polymer (low drug to polymer ratio) 
drug release decreased significantly (see Section 3.1.2) and low degree of drug 
penetration into the deeper layers of the skin might be attributed to slow drug release. 
The small amount of drug penetrated on the upper layer might also be associated with 
low amount of drug release and a high degree of adhesion of the cationic nanoparticles 
to the negatively charged skin surface, which was most likely taken away with the first 
two layers of tape strips. Thus, over longer period of time, slow drug release and 
penetration might be obtained. Therefore, by preparing polymeric nanoparticles and 
controlling the drug to polymer ratio it was possible to control drug release on the skin 
surface, which would also enhance treatment effectiveness of some skin diseases 
using corticosteroids. 
However for nanoparticles, follicular penetration is assumed to be the major 
penetration pathways through the skin and, follicular penetration from excised human 
skin is insignificant because the follicles remained closed after surgical removal of the 
skin (Patzelt et al., 2008b). Thus, penetration of the nanoparticles into deeper layer of 
the hair follicles is expected to improve the degree of penetration of the corticosteroids 
and basically drug release from nanoparticles in the hair follicles is quite slow and a 
more sustained release over an expected period of time is expected in vivo. In addition, 
there is a high concentration of dendritic cells in the follicular walls. Thus in vivo the 
nanoparticles are expected to perform even better. 
 
3. Results and discussion 
67 
 
3.1.4. Toxicity study 
The toxicity study of the polymeric nanoparticles was performed in cooperation with 
the research group of Prof. Dr. Burkhard Kleuser.  
The MTT assay showed that there was no significant reduction in cell viability after 
exposing the cells to 50 and 500 µg/ml Eudragit® RS and ethyl cellulose nanoparticles 
for 24 h and 48 h (Figure 16). In contrast, cell proliferation increased, which can be 
associated with increased cell metabolism as a result of stress response. The same 
effect was observed with high concentrations of the well-established biocompatible and 
biodegradable PLGA nanoparticles (Swed et al., 2014). Oxidative stress triggered by 
nanoparticles is one of the major concerns for inducing genotoxic effects (Nel et al., 
2006). The H2DCFDA assay showed that the Eudragit® RS nanoparticles bear no 
cytotoxicity potential but ethyl cellulose nanoparticles, especially when used at high 
concentration (500 µg/ml) (Figure 17). It has been suggested that the general trend of 
nanomaterials cytotoxicity is similar among various types of nanoparticles and that 
non-specific oxidative stress is one of the largest concerns in nanoparticle-induced 
toxicity (Nel et al., 2006). 
 
Figure 16: Percent cell viability of NHK cells determined by MTT assay after exposing them to different 
concentrations of ethyl cellulose and Eudragit® RS nanoparticles for different period of time. UC = 
untreated cells (negative control) and SDS (positive control). * indicates significant differences from the 
cytotoxicity limit 80%; p < 0.05 




Figure 17: ROS levels in NHK cells after exposing them to different concentrations of ethyl cellulose 
and Eudragit® RS nanoparticles for 1 h as determined by the H2DCFDA assay. UC = untreated cells 
(negative control); PC = positive control (40 nm silver nanoparticles). * p < 0.05 
 
3.1.5. Conclusions 
Promising dexamethasone-loaded ethyl cellulose and Eudragit® RS nanoparticles 
were prepared and characterized. The nanoparticles showed no toxicity potentials ex 
vivo, except ethyl cellulose particles, which exhibited ROS generating potentials. Drug 
release from the nanoparticles could be controlled by choosing appropriate type and 
amount of polymer. Ex vivo, drug release and penetration into the skin from the 
nanoparticles was slower than a commercial cream. Thus, these nanoparticles could 
be used for the delivery of corticosteroids, whereby slow release on the skin surface 
could significantly improve their treatment effectiveness. However, ex vivo drug 
release and penetration investigations using excised human skin might neglect the 
follicular pathway and the results should be supported by in vivo data. 
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3.2. Part II: Sebum-responsive nanoparticles for follicular 
targeting 
Inflammatory processes in and around the hair follicle e.g. follicular psoriasis and 
primary inflammatory hair diseases are challenging skin diseases, because in these 
cases inflammation is located at specific, poorly accessible areas in otherwise 
unaffected skin.  
Solid particles like polymer nanoparticles, lipid nanoparticles and liposomes are known 
to penetrate into open hair follicles (Lademann et al., 2007). Additionally a particle size 
of 300 – 600 nm is optimal for the follicular penetration, because this particle size 
corresponds to the thickness of the overlapping cuticula hair surface (Lademann et al., 
2009; Patzelt et al., 2011).  
Hair follicles are an optimal target for drug delivery, because they represent an efficient 
reservoir for nanoparticles and nanoparticle-based drug delivery as nanoparticles stay 
inside the hair follicle for several days (Lademann et al., 2006). Furthermore dendritic 
cells and other cells, that are involved in inflammatory processes in the skin, can be 
targeted through the follicular route (Lademann et al., 2005; Vogt et al., 2005).  
However the drug release from nanoparticles within a confined environment, for 
example hair follicles, remains a challenge (Lademann et al., 2015). The upper section 
of the hair follicle is mainly filled with sebum, which is secreted by the sebaceous gland 
(Lu et al., 2009). Sebum is a mixture of squalene, waxes, cholesterol derivatives, 
triglycerides, fatty acids and cell debris, which liquefy at 37 °C (Valiveti et al., 2008). 
Therefore sebum could be used to trigger nanoparticle swelling, erosion and 
dissolution and by this increasing the drug release or even lead to pulsatile site-specific 
drug release in the hair follicle.  
The objective of this study was to prepare sebum-responsive nanoparticles, which 
penetrate deeply into the hair follicle and will swell, erode and/or dissolve in sebum to 
trigger the drug release. 
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3.2.1. Screening of sebum-responsive polymers 
The solubility of different polymers in artificial sebum was determined at 60 °C, where 
the artificial sebum is in a molten state and visually clear. The artificial sebum solubility 
of Eudragit® L 100, Eudragit® S 100, HPMCP-55, PLA, PLGA 503, PLGA 503 H, PLGA 
502 S and PVA was < 1% (w/w) and were considered not sufficiently sebum-
responsive for this study. Eudragit® RS particles were small and transparent when 
observed under the microscope and as a result it was difficult to discern if Eudragit® 
RS was soluble enough in the sebum. Consequently Eudragit® RS particles were 
mixed with artificial sebum and observed under the microscope at 37 °C for 16 h. After 
16 h there was no change in particle size or shape of the Eudragit® RS nanoparticles 
(Figure 18) and Eudragit® RS was also considered as insoluble in sebum.  
 
Figure 18: Eudragit® RS particles after 0 h (start) and 16 h incubation time in artificial sebum at 37 °C; 
scale bar 50 µm. 
Interestingly, ethyl cellulose particles dissolved in artificial sebum and when the ethyl 
cellulose concentration increased the solution appeared hazy (Figure 19a-c). However, 
when observed under the microscope all the particles were dissolved up to 20% (w/w) 
ethyl cellulose but some undissolved particles were obtained at 30% (w/w) ethyl 
cellulose (Figure 19d-f). Thus, ethyl cellulose was chosen to prepare and evaluate 
sebum-responsive nanoparticles. 




Figure 19: Macroscopic (a-c) and microscopic (d-f) pictures of artificial sebum (a, d), artificial sebum 
with 20% (w/w) ethyl cellulose (b, e) and 30% (w/w) ethyl cellulose (c, f) at 60 °C after 24 h; scale bar 
50 µm. 
 
3.2.2. Sebum-responsive nanoparticle preparation and size optimization 
All the nanoparticles were prepared by solvent evaporation method. However, the 
follicular penetration of nanoparticles is highly dependent on nanoparticles size and 
nanoparticles in the range of 600 - 700 nm are excellent candidates to target the hair 
follicles (Patzelt et al., 2011). Therefore, the potentials of the two emulsion 
homogenization techniques, namely sonication and high shear homogenization to 
obtain the desired nanoparticle size were assessed. The effect of sonication amplitude 
and sonication time in case of sonication and rotational speed and emulsification time 
in case of high shear homogenization on the particle size and PDI of the prepared ethyl 
cellulose nanoparticles was investigated. 
 
3.2.2.1. Effect of sonication amplitude and sonication time on the particle size 
and PDI 
Sonication is a well established method to produce nanoparticles. Generally the size 
of nanoparticles prepared by sonication is dependent on the ultrasound amplitude and 
sonication time, which determine the total energy input (Abbas et al., 2014).  
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The effect of the amplitude on the particles size and PDI was investigated at a fixed 
sonication time of 2 min and the amplitude was varied from 10% to 25%. The effect of 
the sonication time on the particle size and PDI was studied at a fixed amplitude of 
15% at different sonication times (0.5, 2 and 4 min).  
Both factors had an insignificant effect on the particle size and already a low amplitude 
and a short sonication time led to a small particle size below 250 nm (Figure 20). The 
PDI was in all cases below the limit value of 0.25 for a narrow particle size distribution 
(Tantra et al., 2010). Therefore, sonication was too powerful to prepare ethyl cellulose 
nanoparticles in the range of 600 - 700 nm. 
 
Figure 20: Effect of sonication amplitude (a) and sonication time (b) on the sizes and PDI values of ethyl 
cellulose nanoparticles prepared by sonication for 2 min and 15% ultrasound amplitude, respectively. 
 
3.2.2.2. Effect of rotational speed and emulsification time on the particle size and 
PDI 
High shear homogenization is hardly used to prepare nanoparticles, because often 
high amounts of microparticles are obtained (Mehnert and Mäder, 2001). Nonetheless, 
a number of nanoparticle preparations by high shear homogenization indicate that the 
method is sufficient for the preparation of nanoparticles (Puglia et al., 2013; Triplett 
and Rathman, 2008). The rotational speeds and emulsification times of high shear 
homogenization may determine the particle size and PDI of the obtained nanoparticles. 
Ethyl cellulose nanoparticles were prepared with different rotational speeds and 
emulsification times to investigate their effect on the particle size and PDI. Interestingly 
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rotational speeds below 13,500 rpm gave only microparticles and by varying the 
rotational speed from 13,500 to 24,000 rpm the size of the nanoparticles could be 
controlled in the range of 900 - 400 nm (Figure 21). However, a PDI value of 0.25 was 
only obtained at a high rotational speed of 24,000 rpm and with longer homogenization 
times of 4 - 6 min. Otherwise the PDI was between 0.3 - 0.5 and higher than the limit 
value of 0.25 indicating a relatively broad particle distribution. High shear 
homogenization was an adequate method to control the size of ethyl cellulose 
nanoparticles over a broad range. The PDI values could be adjusted by formulation 
optimization regarding high shear homogenization (Triplett and Rathman, 2008). 
 
Figure 21: Effect of rotational speed and emulsification time on the particle size and PDI of ethyl cellulose 
nanoparticles. 
 
3.2.3. Investigation of polymer sebum interactions 
The changes in the thermal behavior, viscosity and viscoelasticity of the sebum-
responsive and sebum-unresponsive polymers in artificial sebum were thoroughly 
investigated to better understand the sebum-responsive nature of the nanoparticles. 
For the investigation ethyl cellulose and Eudragit® RS were used as sebum-responsive 
and sebum-unresponsive polymers, respectively. 
 
3.2.3.1. Ethyl cellulose microparticle dissolution in artificial sebum 
The swelling, erosion and dissolution of ethyl cellulose microparticles in artificial sebum 
was investigated under the microscope at 37 °C. The prepared ethyl cellulose 
microparticles were composed of 80% (w/w) ethyl cellulose and 20% (w/w) PVA. The 
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d0.1, d0.5 and d0.9 of the microparticles determined by laser diffraction were 3.0, 5.3 and 
9.8 µm, respectively (Figure 22).  
 
Figure 22: Microscopic pictures of ethyl cellulose microparticles (a) and artificial sebum (b) at 37 °C, 
scale bar 50 µm. 
Dispersion of 20% (w/w) ethyl cellulose microparticles in artificial sebum resulted in 
rapid erosion and dissolution of the microparticles where the majority of the 
microparticles dissolved with in less than 2 min. However, complete dissolution of the 
microparticles took 2 h because the system was not subjected to any mixing under the 
microscope (Figure 23).  
 
Figure 23: Microscopic pictures of 20% (w/w) ethyl cellulose microparticles in artificial sebum after 
mixing with artificial sebum at 37 °C at certain time points; scale bar 50 µm. 
The fast dissolution of ethyl cellulose microparticles after mixing with sebum suggests 
that there would be fast dissolution of the sebum-responsive nanoparticles, which have 
an immense surface area to volume ratio. Furthermore sebum-triggered drug release 
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from the ethyl cellulose nanoparticles inside the upper section of the hair follicle and 
the sebaceous glands, which are filled with sebum is expected (Lu et al., 2009).  
 
3.2.3.2. Effect of ethyl cellulose and Eudragit® RS nanoparticles on the thermal 
properties of artificial sebum 
The Tg of PVA, ethyl cellulose and Eudragit® RS was 68 °C, 119 °C and 42 °C, 
respectively (Figure 24). The physical mixture of ethyl cellulose:PVA (8:2) and ethyl 
cellulose nanoparticles exhibited a Tg value close to the Tg value of ethyl cellulose and 
the Tg of PVA vanished indicating good miscibility of the polymers (Lu and Weiss, 
1992). Nevertheless, the amount of PVA inside the physical mixture and the ethyl 
cellulose nanoparticle formulation was low and could be below the detection limit of 
the DSC. Contrarily, the physical mixture Eudragit® RS:PVA (8:2) and Eudragit® RS 
nanoparticles exhibited a Tg at 64 °C, which was slightly lower and broader than the 
PVA peak but higher and narrower than the Eudragit® RS Tg. The changes in the Tg 
in case of physical mixtures of Eudragit® RS:PVA (8:2) and Eudragit® RS nanoparticle 
formulation indicated a good miscibility of the polymers with plasticizing effect between 
them.  
 
Figure 24: DSC thermograms of PVA, ethyl cellulose, Eudragit® RS, physical mixtures (8:2) of ethyl 
cellulose and Eudragit® RS with PVA, ethyl cellulose nanoparticles and Eudragit® RS nanoparticles. 




Figure 25: DSC thermograms of artificial sebum and artificial sebum with 4% (w/w) PVA, 20% (w/w) 
ethyl cellulose nanoparticles and 20% (w/w) Eudragit® RS nanoparticles. 
The artificial sebum exhibited a broad melting peak (Figure 25), because it is a complex 
mixture with waxy materials like human sebum. Therefore, sebum is lacking a sharp 
melting peak (Lu et al., 2009). Mixing 4% (w/w) PVA (corresponding to the PVA amount 
in 20% (w/w) nanoparticle formulation), 20% (w/w) ethyl cellulose and 20% (w/w) 
Eudragit® RS nanoparticles with artificial sebum did not affect the thermal behavior of 
the artificial sebum as the broad melting peak of the artificial sebum remained 
unchanged (Figure 25). Furthermore, Tg peaks of PVA, ethyl cellulose and Eudragit® 
RS were not visible. This could indicate that the ethyl cellulose nanoparticles were 
dissolved within the artificial sebum. In the case of Eudragit® RS nanoparticles and 
PVA which were insoluble in artificial sebum (see section 3.2.1.) the Tg could be shifted 
below 50 °C due to the plasticizing effect of the artificial sebum and mixed with the 
broad melting peak of the artificial sebum. However, the amount of ethyl cellulose, 
Eudragit® RS and especially of PVA could be below the detection limit of the DSC, too. 
 
3.2.3.3. Effects of ethyl cellulose and Eudragit® RS nanoparticles on the 
rheological properties of artificial sebum 
The effect of nanoparticles on the rheological properties of sebum can be diverse, 
because on the one hand, sebum is complex mixture of waxy and liquid components 
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(Lu et al., 2009) and on the other hand there could be interaction between sebum and 
nanoparticles, between solid and liquid structures inside the sebum and between the 
nanoparticles itself. 
The viscosity of artificial sebum decreased with increasing shear rates. Hence, artificial 
sebum is a non-Newtonian fluid with a shear thinning flow behavior (Figure 26). The 
artificial sebum had a pseudo plastic flow behavior with a yield stress as it only started 
to flow when a certain stress value was exceeded (Figure 27). Furthermore, the 
viscosity decreased with time under shear stress characterizing a thixotropic flow 
behavior (Figure 26).  
 
Figure 26: Viscosity as a function on shear rate of artificial sebum and artificial sebum mixtures with 
PVA, ethyl cellulose nanoparticles and Eudragit® RS nanoparticles at 37 °C. 




Figure 27: Shear stress as a function of shear rate of artificial sebum and artificial sebum mixtures with 
PVA, ethyl cellulose nanoparticles and Eudragit® RS nanoparticles at 37 °C. 
Addition of PVA, ethyl cellulose nanoparticles and Eudragit® RS nanoparticles had no 
effect on the shear thinning pseudo plastic thixotropic flow behavior of the artificial 
sebum. 2% (data not shown) and 4% (w/w) PVA in artificial sebum had an insignificant 
effect on the viscosity of artificial sebum what correspond to the amount of PVA after 
the addition of 10% and 20% (w/w) nanoparticle formulation to artificial sebum, 
respectively. However, in case of ethyl cellulose and Eudragit® RS nanoparticles the 
viscosity of the artificial sebum increased proportional to the percentage of 
nanoparticles added (Figure 26).  
Generally, ethyl cellulose nanoparticles increased the viscosity of the artificial sebum 
more than Eudragit® RS nanoparticles due to their dissolution in the sebum unlike the 
Eudragit® RS nanoparticles. In fact ethyl cellulose is an established gelling agent in 
oils (Davidovich-Pinhas et al., 2015). The increased viscosity in case of Eudragit® RS 
nanoparticles can also be explained by the Krieger-Dougherty equation (Equation 1).  
 





= (1−  φ
φm
)− [η]φm Equation 1 
where ƞ is the viscosity of the suspension, ƞ0 is the viscosity of the medium, [ƞ] is the 
intrinsic viscosity (2.5 for spheres), φ is the volume concentration of particles, φm is φ 
at the maximum packing.  
The viscosity increases at high volume fraction of the dispersed phase (φ) as the 
particles become more closely packed and their free movement is hindered. 
Additionally charged nanoparticles increase the viscosity higher than uncharged 
nanoparticles, because charge increases the effective diameter of particles, what is 
comparable to an increase of the volume fraction of already constrained particles 
(Heine et al., 2010). 
The viscoelastic behavior of the artificial sebum alone and when mixed with PVA, ethyl 
cellulose nanoparticles or Eudragit® RS nanoparticles was investigated by amplitude 
sweep tests. Thereby the ability of artificial sebum to store energy, what characterize 
an elastic behavior of solids (storage modulus, G´), and to dissipate energy as it flows, 
what characterize a viscous behavior of liquids (loss modulus, G´´), was measured.  
At low strains the storage modulus (G´) values were bigger than the loss modulus (G´´) 
values indicating a gel like behavior of a viscoelastic solid. The intersection of the G´ 
and G´´ curve at higher strains is the gel-sol transition point where the gel structure of 
the artificial sebum was liquefied. After the gel-sol transition point the G´´ values were 
bigger than the G´ values indicating the viscoelastic behavior of a liquid (Figure 28).  




Figure 28: Storage and loss moduli as a function of strain of artificial sebum and artificial sebum mixtures 
with PVA, ethyl cellulose and Eudragit® RS nanoparticles at 37 °C. 
2% and 4% (w/w) PVA in artificial sebum had an insignificant effect on the viscoelastic 
properties of artificial sebum. The addition of 10% (w/w) ethyl cellulose nanoparticles 
to artificial sebum slightly increased the viscosity and the G´´ values especially at high 
stress and strain values. Increasing the ethyl cellulose nanoparticles amount to 20% 
(w/w) increased both, the G´ and the G´´, values. The distance between G´ and G´´ 
values decreased and the gel-sol transition point shifted to a lower strain after the 
addition of ethyl cellulose nanoparticles and with increasing ethyl cellulose 
nanoparticle concentrations in comparison to artificial sebum (Table 5). Thus, the gel 
like structure of the artificial sebum was preserved after the addition of ethyl cellulose 
nanoparticles. However, the smaller difference of G´ and G´´ and the shift in the gel-
sol transition point after addition of ethyl cellulose nanoparticles suggest that the 
interactions inside sebum, which formed the gel like structure were disturbed by ethyl 
cellulose, because the gel like structure liquefied under smaller strain values in 
comparison to artificial sebum. 
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Table 5: Gel-sol transition points of artificial sebum and artificial sebum mixtures with PVA, ethyl 
cellulose nanoparticles and Eudragit® RS nanoparticles  
Mixture Gel-sol transition point (Strain, %) 
Sebum 17.63% ± 3.35% 
Sebum + 2% (w/w) PVA 13.67% ± 2.87% 
Sebum + 4% (w/w) PVA 14.53% ± 1.50% 
Sebum + 10% (w/w) ethyl cellulose nanoparticles 1.96% ± 0.89% 
Sebum + 20% (w/w) ethyl cellulose nanoparticles 0.67% ± 0.03% 
Sebum + 10% (w/w) Eudragit® RS nanoparticles 4.78% ± 1.12% 
Sebum + 20% (w/w) Eudragit® RS nanoparticles 2.06% ± 0.57% 
The addition of 10% (w/w) Eudragit® RS nanoparticles had no effect on the viscoelastic 
properties of the artificial sebum. However, 20% (w/w) Eudragit® RS nanoparticles 
increased the G´ and G´´ value (Figure 28) and the gel-sol transition point decreased 
to lower strain values by increasing the amount of Eudragit® RS nanoparticles (Table 
5). The effect was less pronounced in comparison to ethyl cellulose nanoparticles, 
which dissolve inside sebum what increase possible interferences. It indicated that, 
although Eudragit® RS nanoparticles were insoluble inside sebum, the high amounts 
of undissolved nanoparticles perturb the gel organization by their accommodation and 
decreased the rigidity and viscoelasticity of the gel-like structure of the artificial sebum 
(Pal et al., 2009). 
Nanoparticles deeply penetrate into hair follicles, because of the pumping and ratchet 
effect of the hair follicle surface structure (Patzelt et al., 2011; Radtke et al., 2017). 
Furthermore, nanoparticles remain inside the hair follicle for up to 10 days, because of 
the slow sebum flow out of the hair follicle (Lademann et al., 2006; Lademann et al., 
2007). However, the examined effects of nanoparticles on the rheological properties 
of artificial sebum could be another reason. The shift in gel-sol transition to lower 
strains by their interaction with the sebum potentially led to a liquefied sebum due to 
the hair movement and a deeper penetration of the nanoparticles. The increase in 
sebum viscosity potentially reduce the sebum flow out of the hair follicle and increase 
the nanoparticle retaining time inside the hair follicle. 
Nevertheless, the effect of nanoparticles on the rheological properties of sebum could 
led to hair follicle and skin irritations, as sebum is a significant factor for example in the 
acne formation (Youn, 2010).  
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3.2.4. In vitro drug release 
The in vitro drug release of the different dexamethasone-loaded nanoparticles namely, 
nanocrystals, Eudragit® RS and ethyl cellulose nanoparticles (Table 6) was 
investigated with Franz diffusion cells. During the measurement the regenerated 
cellulose membrane, which was mounted on the Franz diffusion cells, was soaked in 
water, paraffin or artificial sebum to investigate the effect of paraffin and artificial sebum 
on the in vitro drug release of the different nanoparticles. 
Table 6: Composition, size, PDI and loading capacity of the different nanoparticles investigated that 
contained 0.06% (w/w) dexamethasone. 
Nanocarrier Composition Z-Average 
(nm) 
PDI Loading capacity 
(%) 
Nanocrystals 0.5% (w/v) PVA 355 0.150 - 
Eudragit® RS 
nanoparticles 
5% (w/w) Eudragit® RS,   
1.25% (w/v) PVA 




2% (w/w) ethyl cellulose,   
0.5% (w/v) PVA 




5% (w/w) ethyl cellulose,  
1.25% (w/v) PVA 
168 0.143  0.9 
The solubility of dexamethasone in water, paraffin and artificial sebum at 60 °C was 
157 ± 12 µg/ml (examined quantitative), 50 µg/ml and 100 µg/ml (examined half 
quantitative), respectively. Its paraffin/water and sebum/water partitioning coefficient 
at 37 °C was 0.25 ± 0.08 and 0.96 ± 0.12, respectively. Dexamethasone nanocrystals 
were used as control to investigate the effect of artificial sebum on the dexamethasone 
partitioning between donor and acceptor compartment. The paraffin soaked membrane 
was used as solvent control, because ethyl cellulose is insoluble in paraffin. The 
amount of paraffin and artificial sebum on the membranes after soaking them for 15 h 
was 131 ± 31 mg and 49 ± 14 mg, respectively. 
Membrane soaking had no significant effect on the in vitro drug release of 
dexamethasone nanocrystals (Figure 29a). This result indicated that neither the 
additional lipid layer as compartment with a partition coefficient between the donor and 
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acceptor nor the higher viscosity of the artificial sebum compartment had an effect on 
the dexamethasone partitioning from donor to acceptor compartment. 
 
Figure 29: In vitro drug release of dexamethasone nanocrystals (a), dexamethasone-loaded 
Eudragit® RS nanoparticles with 1% loading capacity (b), dexamethasone-loaded ethyl cellulose 
nanoparticles with 2% loading capacity (c) and dexamethasone-loaded ethyl cellulose nanoparticles 
with 1% loading capacity (d) investigated with Franz-diffusion cells with regenerated cellulose 
membranes soaked with artificial sebum, paraffin or water. 
The dexamethasone release from Eudragit® RS nanoparticles was significantly slower 
with artificial sebum soaked membranes compared to the water and paraffin soaked 
membranes. However, there was no significant difference in drug release between 
water and paraffin soaked membranes (Figure 29b). The slower dexamethasone 
release from Eudragit® RS nanoparticles with artificial sebum soaked membrane 
indicated an interaction between sebum and Eudragit® RS nanoparticles, which 
decreased the drug release. Potentially the increased viscosity of the artificial sebum, 
after the addition of Eudragit® RS nanoparticles (Figure 26) decreased the 
dexamethasone release of Eudragit® RS nanoparticles what can be explained by the 
Stokes-Einstein equation (Equation 2). The higher viscosity of artificial sebum with 
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Eudragit® RS nanoparticles reduced the dexamethasone diffusion coefficient, release 
and partitioning into the donor compartment. 
𝐷𝐷 = 𝑘𝑘 × 𝑇𝑇6 × 𝜋𝜋 × 𝜂𝜂 × 𝑟𝑟 Equation 2 
where D is the diffusion coefficient, k the Boltzmann´s constant, T the absolute 
temperature, η the viscosity of the media and r the radius of the dissolved molecule. 
The dexamethasone release from ethyl cellulose nanoparticles was significantly faster 
with artificial sebum soaked membranes compared to paraffin and water soaked 
membranes, because ethyl cellulose nanoparticles dissolved in the artificial sebum and 
released the drug faster (Figure 29c and d). The higher viscosity of artificial sebum 
with ethyl cellulose nanoparticles (Figure 26) did not reduced the dexamethasone 
release of the ethyl cellulose nanoparticles in contrast to Eudragit® RS nanoparticles, 
because the fast dissolution of ethyl cellulose nanoparticles after the contact with 
sebum resulting in a fast drug release, overruled the effect of the increased viscosity. 
Interestingly the drug release decreased considerably with decreasing loading 
capacity, because a lower loading capacity was achieved by increasing the amount of 
the polymer in the disperse phase to keep the amount of suspension applied in the 
donor phase constant. Therefore the applied polymer amount increased resulting in a 
higher viscosity of the artificial sebum decreasing the dexamethasone release. 
The dexamethasone release of ethyl cellulose nanoparticles with paraffin and water 
soaked membranes was slower compared to sebum soaked membrane because 
dexamethasone-loaded ethyl cellulose nanoparticles did not dissolve in water and 
paraffin. Therefore the dexamethasone is released in a diffusion controlled manner of 
the matrix structure of the ethyl cellulose nanoparticles. The drug release decreased 
with decreasing loading capacity, too because there is a high degree of drug 
encapsulation and probable formation of a high tortuous path (Figure 29c and d).  
 
3.2.5. Ex vivo follicular penetration study 
The ex vivo follicular penetration of the nanoparticles was performed in cooperation 
with the research group of Prof. Dr. Dr.-Ing. Jürgen Lademann using porcine ear skin, 
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because the hair follicle remains open after the surgical removal in contrast to human 
skin. In human skin, the skin contracts after surgical removal and as a result the hair 
follicles remain closed (Patzelt et al., 2008b). Furthermore, porcine tissue has a 
comparable tissue structure to human skin and is therefore a suitable ex vivo model to 
human skin (Jacobi et al., 2007). 
The ex vivo follicular penetration of aqueous 5% (w/w) ethyl cellulose and 5% (w/w) 
Eudragit® RS nanosuspensions with 1.25% PVA (w/v) was investigated (Figure 30).  
 
Figure 30: Typical CLSM images of a histological section of a porcine ear skin containing a hair follicle: 
red fluorescence emission image of a) untreated hair follicle, b) hair follicle treated with Nile red-loaded 
ethyl cellulose nanoparticles and c) Eudragit® RS nanoparticles and the superimposed image of the 
transmittance mode and the fluorescence emission image of d) untreated hair follicle, e) hair follicle 
treated with ethyl cellulose nanoparticles and f) Eudragit® RS nanoparticles. 
Both nanoparticles were loaded with 0.004% (w/w) Nile red and the sizes of the ethyl 
cellulose and Eudragit® RS nanoparticles were 159 ± 1 nm and 90 ± 1 nm, respectively. 
The PDI values were 0.132 ± 0.009 and 0.211 ± 0.002, respectively. Furthermore, the 
ethyl cellulose nanoparticles were investigated with n-hexane washed and Sebutape® 
tapped skins, what reduce the sebum amount on skin and inside the hair follicles 
(Campbell et al., 2012; Pagnoni et al., 1994).  
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The hair follicular penetration depth of ethyl cellulose and Eudragit® RS nanoparticles 
was comparable (285 ± 75 µm and 306 ± 30 µm, respectively). This was expected as 
the nanoparticles had comparable particle sizes, the main factor that determines the 
hair follicular penetration depth of nanoparticles (Patzelt et al., 2011).  
The fluorescence intensity of ethyl cellulose nanoparticles inside the hair follicles in 
untreated porcine ear skin was higher than in sebum reduced porcine ear skin (Figure 
31).  
 
Figure 31: Fluorescence intensity inside porcine ear skin hair follicles of untreated skin, untreated skin 
with Nile red-loaded ethyl cellulose and Eudragit® RS nanoparticles, n-hexane washed skin with Nile 
red-loaded ethyl cellulose nanoparticles and Sebutape® tapped skin with Nile red-loaded ethyl cellulose 
nanoparticles. 
This is in line with the in vitro results that the sebum dissolved ethyl cellulose 
nanoparticles inside the hair follicle and the fluorescent dye is released quickly. Without 
sebum, the ethyl cellulose nanoparticles remain intact and the dye is released slower 
(Figure 29). Additionally the fluorescence intensity of Eudragit® RS nanoparticles was 
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lower inside the hair follicles with untreated porcine ear skin in comparison to ethyl 
cellulose nanoparticles (Figure 31). Eudragit® RS nanoparticles were insoluble in 
sebum and sebum reduced the drug release of Eudragit® RS nanoparticles in contrast 
to ethyl cellulose nanoparticles (Figure 29), what is reflected by the ex vivo follicular 
penetration study. The difference in fluorescence intensity of the released dye and the 
dye inside the nanoparticles can be explained by the self-quenching between the 
unreleased fluorescence molecules inside the nanoparticles what reduces the 
fluorescence intensity (Imhof et al., 1999).  
 
3.2.6. Conclusions 
Promising sebum-responsive polymeric nanoparticles were prepared and 
characterized. Ethyl cellulose was the only sebum soluble polymer among the ten 
different polymers screened. Ethyl cellulose exhibited a sebum solubility of 20% (w/w) 
without changing the thermal behavior of the artificial sebum. Ethyl cellulose 
microparticle dissolved fast inside artificial sebum and the in vitro drug release of 
dexamethasone-loaded ethyl cellulose nanoparticles was increased in sebum. Ex vivo 
Nile red-loaded ethyl cellulose nanoparticles exhibited a higher fluorescence intensity 
in hair follicles of untreated porcine ear skin than in sebum reduced porcine ear skin. 
These results indicated that ethyl cellulose nanoparticles will dissolve inside hair 
follicles after coming in contact with sebum and release the loaded drug close to the 
target site. 
Therefore, sebum-responsive ethyl cellulose nanoparticles could be established which 
could improve the treatment efficiency of drugs for hair follicle associated skin 
diseases. Ethyl cellulose nanoparticles will penetrate into the hair follicle and after 
contact with sebum release the loaded drug in close proximity to the target structure.  
However, CLSM is a semi-quantitative method and it is difficult to exactly quantify the 
amount of dye that was released by the nanoparticles. Thus, this method should be 
complemented with other sensitive, precise and accurate analytical ex and in vivo 
methods to further investigate the clinical potential of ethyl cellulose nanoparticles. 
Nevertheless, the viscosity of artificial sebum increased and the viscoelastic behavior 
changed after the addition of ethyl cellulose nanoparticles. Therefore, the irrational 
3. Results and discussion 
88 
 
potential to skin and hair follicle of ethyl cellulose nanoparticles should be investigated 
in vivo.
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3.3. Part III: Comparison of in vitro drug release methods4 
 
In vitro drug release is one of the most important methods used to assess the quality 
of and estimate the in vivo performance of a nanocarrier. To date, there is no 
compendial method available to evaluate drug release from various pharmaceutical 
nanocarriers. Consequently, various in vitro drug release techniques have been used. 
These methods can be broadly categorized in sample and separate, dialysis 
membrane, and in situ methods (D’Souza, 2014).  
The different techniques may give different results as the methods are different in their 
working principles and even with the same method different results might be obtained 
when working under sink and non-sink conditions (Mishra et al., 2009; Murdande et 
al., 2015). 
The choice of a drug release method for analysis of nanocarriers has in most cases 
been random without giving an account about their reproducibility and ability to 
discriminate release between different dosage forms. Therefore, the objective of this 
study was to assess and compare the reproducibility and discrimination potentials of 
three in vitro drug release methods, namely dialysis bags, Franz diffusion cells and the 
in situ drug release Sirius® inForm apparatus. The nanocarriers investigated include 
nanocrystals, polymeric nanoparticles and lipid nanoparticles under sink and non-sink 
conditions. Furthermore, the obtained in vitro results were correlated with ex vivo 
experiments with excised human skin to investigate the clinical relevance of the in vitro 
results. 
 
3.3.1. Nanocarrier formulation and characterization 
Different types of dexamethasone-loaded nanocarriers with different properties were 
prepared for the release experiments (Table 7).  
As expected, the viscosity of the nanocrystals and ethyl cellulose nanosuspensions 
increased upon formulating them into HEC gels and their flow behavior changed from 
                                            
4 Parts of this chapter were taken from: B. Balzus, M. Colombo, F.F. Sahle, G. Zoubari, S. Staufenbiel, 
R. Bodmeier, Comparison of different in vitro release methods used to investigate nanocarriers intended 
for dermal application, Int. J. Pharm., 513 (2016) 247-254. 
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Newtonian to shear-thinning type (Figure 32). The increase in viscosity was 
proportional to the concentration of HEC used. Microscopic observations and dynamic 
light scattering results showed that the nanocarriers did not agglomerate upon addition 
of HEC. 
Table 7: Composition, size, PDI and encapsulation efficiency of the investigated nanocarriers containing 
0.05% (w/w) dexamethasone. 




Nanocrystals 0.49% (w/v) 
poloxamer 407 
268 ± 8 0.127 ± 0.041 - 
Lipid nanoparticles 7.5% (w/w) Gelucire®, 
2.5% (w/w) Witepsol®  
112 ± 13 0.186 ± 0.133  93.6 ± 0.9 
Eudragit® RS 
nanoparticles 
5% (w/w) Eudragit®  
RS,  2.5% (w/v) PVA 
70 ± 1 0.200 ± 0.008 66.8 ± 0.4 
Ethyl cellulose 
nanoparticles 
5% (w/w) ethyl 
cellulose, 2.5% (w/v) 
PVA 
140 ± 1 0.119 ± 0.008  88.2 ± 0.1 
 
 
Figure 32: Rheological properties of nanocrystals and ethyl cellulose nanoparticles before and after 
incorporation of different amount of HEC. 
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However, the size of the ethyl cellulose nanoparticles decreased from 140 nm to 88 
nm and 71 nm and the PDI values increased from 0.119 to 0.216 and 0.283, 
respectively, upon incorporation of 2.5% and 5.0% (w/w) HEC. This could be attributed 
to the addition of a relatively high amount of the polymer HEC, which affected the 
average particle size obtained with the dynamic light scattering. The dynamic light 
scattering data of the 2.5% and 5.0% HEC dispersion prepared by the same method 
but without the nanocarriers gave sizes of 40 ± 2 nm and 26 ± 2 nm, respectively. As 
a result, the average size of the peak decreased and the PDI increased. 
 
3.3.2. Drug release investigations and method comparison 
3.3.2.1. In situ drug release investigation using Sirius® inForm 
Sirius® inForm is a relatively new instrument which is designed to carry out a number 
of formulation and preformulation investigations, including drug release studies, in a 
short period of time. Accordingly, its potential use in assessing dexamethasone release 
in situ from colloidal dispersions of nanocrystals, lipid nanoparticles and Eudragit® RS 
nanoparticles under sink and non-sink conditions was assessed (Figure 33).  
 
Figure 33: Dexamethasone release from different nanocarriers under sink and non-sink conditions as 
investigated in situ by using Sirius® inForm. 
However, drug release was completed in few seconds and no significant difference in 
drug release between the nanocarriers was observed. Besides, drug release from ethyl 
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cellulose nanoparticles could not be investigated both under sink and non-sink 
conditions due to the high background scattering caused by the dispersed 
nanoparticles, which significantly interfered with the UV readings. 
In situ drug release from lyophilized nanocrystals and Eudragit® RS nanoparticles was 
also investigated under sink condition (Figure 34). 
 
Figure 34: Dexamethasone release from freeze-dried nanocrystals and Eudragit® RS nanoparticles 
under sink conditions as investigated in situ by using Sirius® inform. 
Like with the liquid nanocarrier dispersions, no significant difference in drug release 
between the nanocarriers was observed. However, the release/dissolution from/of the 
freeze-dried nanocarriers was slower because of the time need for nanocarrier wetting 
and drug dissolution. The nanocrystals and Eudragit® RS nanoparticles were 
redispersible without any significant change in particle size (289.7 nm; PDI 0.068 and 
72.8 nm; PDI 0.209, respectively). 
 
3.3.2.2. In vitro drug release investigation using Franz diffusion cells 
The Franz diffusion cell is a commonly used apparatus to assess release of drugs from 
various dosage forms intended for application to the skin. The release from 
nanocrystals and Eudragit® RS nanoparticles was faster than from lipid nanoparticles 
and ethyl cellulose nanoparticles under both sink and non-sink conditions (Figure 35). 




Figure 35: Dexamethasone release from different nanocarriers under sink and non-sink conditions 
investigated with Franz diffusion cells (n=4, mean ± SD). 
With nanocrystals, the dispersion phase is saturated with the drug and a burst release 
as a result of dissolved drug is expected. Faster drug release is also expected with 
Eudragit® RS nanoparticles due to low drug encapsulation efficiency and their more 
hydrophilic character. The release profiles clearly reflect these phenomena showing 
that the method is discriminative. However, both under sink and non-sink conditions, 
there was no significant difference in drug release between nanocrystals and Eudragit® 
RS nanoparticles and between lipid nanoparticles and ethyl cellulose nanoparticles. 
This suggests that the nanocarriers exhibited similar drug release or the method is not 
adequate to show the differences in drug release. 
 
3.3.2.3. In vitro drug release investigation using dialysis bags 
Assessment of dexamethasone release from the different nanocarriers using dialysis 
bags indicated that, unlike Franz diffusion cell experiments, under both sink and non-
sink conditions drug release from nanocrystals was faster than the drug release from 
Eudragit® RS nanoparticles (Figure 36). 




Figure 36: Dexamethasone release from different nanocarriers under sink and non-sink conditions 
investigated with dialysis bags. 
In addition, like with Franz diffusion cell experiments, release from nanocrystals and 
Eudragit® RS nanoparticles was faster than from lipid nanoparticles and ethyl cellulose 
nanoparticles although there was no significant difference in drug release between the 
lipid nanoparticles and ethyl cellulose nanoparticles, especially under non-sink 
conditions. 
Although the dialysis bag method is more discriminative it was also associated with 
some drawbacks. The method was less reproducible than the Franz diffusion cell 
experiments as shown by the larger error bars on the release profile curves (Figure 35 
and Figure 36). This can be due to a lack of complete control over the area of the 
diffusion membrane unlike with the Franz diffusion cell, which is always given by the 
size of the diameter of the cell. In addition, during the release experiments the volume 
of the colloidal dispersion in the dialysis bags decreased significantly. The volume 
shrinkage was associated to water diffusion from the donor compartment into the 
acceptor compartment due to osmolality differences. Thus drug release using dialysis 
bags would also be significantly affected by the osmolality differences between the 
donor and acceptor media. 
Another problem observed with both dialysis bags and Franz diffusion cells was that 
under non-sink conditions the nanocrystals agglomerated in the donor compartment 
during the release experiments (Figure 37a and Figure 37b). 




Figure 37: Agglomerates of nanocrystals detected after in vitro release experiments conducted under 
non-sink conditions: a) microscopic images in dialysis bags, b) microscopic images on the surface of 
Franz diffusion cell membrane, c) images on the surface of Franz diffusion cell membrane-experiment 
conducted after adjusting the osmolality of the donor compartment. 
The instability could be associated to the differences in medium osmolality in the donor 
and acceptor compartments, which might cause diffusion of electrolytes from the 
acceptor compartment into the donor compartment, which could have a salting out 
effect on the dispersed nanocarriers, and/ or rapid diffusion of the stabilizer from the 
donor compartment into the acceptor compartment. To better understand this a set of 
experiments were conducted. Adjusting the osmolality of the donor compartment to 
that of the acceptor compartment with sodium chloride resulted in rapid particle 
agglomeration even before the start of the release experiment. A significant decrease 
of zeta potential from -12.7 ± 0.1 mV to  -2.7  ± 0.3 mV (poor data quality due to particle 
agglomeration) was also observed. At the end of the release experiment, few large 
fluffy agglomerates formed (Figure 37c). The same agglomerates were also formed on 
the surface of the membrane, which could only be observed under the microscope, 
when water or a 0.49% (w/v) poloxamer solution was used in place of pH 7.4 
phosphate buffer in the acceptor compartment. However, drug release was 
significantly faster when the 0.49% (w/v) poloxamer solution was used (Figure 38). 
This indicated that diffusion of the surfactant contributed to the nanocrystal 
agglomeration. 




Figure 38: Effect of type of the release media in acceptor compartment and the osmolality of the release 
media in the donor compartment in Franz diffusion cells on dexamethasone release from nanocrystals 
under non-sink conditions. 
 
3.3.2.4. Drug release from nanocarriers formulated into HEC gels 
For easy application onto the skin it is advantageous to formulate nanocarriers into 
semisolid dosage forms like gels or creams. Thus, the drug release from HEC gels of 
nanocrystals and ethyl cellulose nanoparticles was investigated using Franz diffusion 
cells under non-sink condition (Figure 39). Interestingly, the method was adequate to 
discriminate dexamethasone release from the HEC gels and between nanocarriers. As 
expected, the release decreased with increasing HEC concentration and was more 
rapid with the nanocrystals. 
The dexamethasone flux from nanocrystals and ethyl cellulose nanoparticles also 
decreased by  ~2 and  ~1.5 folds, respectively, when the aqueous suspensions were 
formulated into 2.5% (w/w) HEC gel (Figure 40). However, increasing the HEC 
concentration from 2.5% to 5.0% (w/w) did not affect drug flux significantly. The 
difference in drug release between nanocrystals and ethyl cellulose nanoparticles is 
significant at all HEC concentrations. 




Figure 39: Dexamethasone release from HEC gels of nanocrystals and ethyl cellulose nanoparticles 
investigated with Franz diffusion cells under non-sink conditions. 
 
Figure 40: Effect of viscosity of the continuous phase on flux of dexamethasone from nanocrystals and 
ethyl cellulose nanoparticles through Franz diffusion cell membrane. 
However, it was not easy to use dialysis bags for the investigation of drug release from 
the gels because of the difficulty to uniformly distribute the gels inside the dialysis bags. 
The Sirius® inForm was also not used for gels because of rapid dispersion of the gels 
in the dissolution vessel. 
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To summarize, each in vitro release method has its advantages and drawbacks and 
discriminates drug release to a different extent (Table 8). 
Table 8: Summary of advantages/disadvantages of the different methods used to investigate drug 
release from different nanocarriers. 
Attribute Release Method 
In situ drug release -  
Sirius® inForm 
Franz diffusion cell Dialysis bag 
Discriminative power No (very rapid drug 
release) 
Yes  Yes 
Release duration < 10 min 24 - 48 h 48 - 72 h 
Simplicity Sophisticated 
instrument, simple set 
up 
Longer set-up time Intermediate 




Easily used with both 
colloidal dispersions 
and semisolids 
More tedious to use 
with semisolids 
Membrane  No Fixed surface area, 
release control by 
membrane?  
Variable surface area, 
osmolality effects on 
bag volume?, release 
control by membrane?  
Reproducibility Good (sometimes too 
high background 
scattering) 
Good (because of 
constant surface area) 
More variability 





3.3.2.5. In vitro - ex vivo correlation of drug release/penetration experiments 
The in vitro drug release experiments revealed a significant difference in 
dexamethasone dissolution/release profiles between nanocrystals and ethyl cellulose 
nanoparticles. To examine if this difference in drug dissolution/release from 
nanocrystals and ethyl cellulose nanoparticles is potentially consistent with their in vivo 
performance dexamethasone dissolution/release and penetration of both 
nanoparticles were investigated ex vivo with excised human skin in cooperation with 
the research groups of Prof. Dr. Sarah Hedtrich and of PD Dr. med. Annika Vogt. The 
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ex vivo experiments were performed with two different methods: Franz diffusion cell 
method and intradermal microdialysis (Figure 41). 
 
Figure 41: a) Franz diffusion cell experiment with excised human skin: Dexamethasone amount in 
epidermis and dermis extracts 6 h after topical application of ethyl cellulose nanocarriers and 
nanocrystals (5 μg/cm2, n = 4). b) Intradermal microdialysis experiment with excised human skin: 
Dexamethasone concentration (μg/ml) in dermis eluates 6, 12 and 24 h after topical application of 5 
μg/cm2 dexamethasone (Döge et al., 2016) 
Using Franz diffusion cell method with excised human skin, the amount of 
dexamethasone penetrated into the epidermis and dermis was determined. In contrast, 
intradermal microdialysis allowed the continuous monitoring of drug penetration and 
was used to examines the drug dissolution/release kinetic of nanocarriers into the 
dermis. 
In the Franz diffusion cell experiments, with dexamethasone nanocrystals and ethyl 
cellulose nanoparticles, an insignificant amount of dexamethasone was recovered in 
the acceptor compartment. With nanocrystals more dexamethasone was recovered in 
epidermis and dermis in comparison to ethyl cellulose nanoparticles 6 h after topical 
application indicating a faster dexamethasone penetration of nanocrystals.  
In the intradermal microdialysis experiments the dexamethasone release into the 
dermis was faster from nanocrystals in comparison to ethyl cellulose nanoparticles. 
3. Results and discussion 
100 
 
Already after 6 h high dexamethasone concentrations in the dermis were detected with 
nanocrystals which was in line with the ex vivo Franz diffusion cell results. In the case 
of ethyl cellulose nanoparticles dexamethasone release was slower and only after 12 h 
a higher dexamethasone concentration in the dermis was reached.  
Results of both ex vivo experiments were consistent with the results of in vitro drug 
release experiments where the dexamethasone dissolution of nanocrystals was 




Dialysis bag and Franz diffusion cell method discriminated drug release from different 
nanocarriers but not the in situ method using the Sirius® inForm. Drug release 
investigation using Franz diffusion cells had better repeatability/reproducibility than the 
release assessment performed using dialysis bags. The drug release profiles of the 
nanocarriers obtained with the different methods at both sink and non-sink conditions 
were not the same. However, the drug dissolution/release from nanocrystals and ethyl 
cellulose nanoparticles with all investigated methods was significantly different, except 
with the in situ method. Ex vivo experiments with human skin using Franz diffusion 
cells and intradermal microdialysis revealed that the difference between nanocrystals 
and ethyl cellulose nanoparticles was consistent with their ex vivo performance. In 
conclusion the investigated dialysis methods (Franz diffusion cell and dialysis bag 
methods) can be used to discriminate drug release profiles of nanocarriers that might 






Controlled delivery of corticosteroids to the skin and hair follicle using nanoparticles 
may reduce their side effects and maximize treatment effectiveness. To assess the 
quality of nanoparticles and estimate their in vivo performance, in vitro drug release 
measurement is one of the most important methods. 
Dexamethasone-loaded polymeric nanoparticles should be prepared, which adhere 
well to the skin and release the drug slowly, in a controlled manner. Additionally, 
sebum-responsive nanoparticles should be prepared, which are able to penetrate deep 
into the hair follicle and release the drug triggered by their dissolution in sebum.  
The discriminative power and reproducibility of three in vitro drug release methods for 
nanoparticles, namely dialysis bags, Franz diffusion cells and an in situ drug release 
method using Sirius® inForm apparatus should be assessed. The investigated 
nanoparticles were nanocrystals, polymeric nanoparticles and lipid nanoparticles. 
Dexamethasone-loaded ethyl cellulose, Eudragit® RS and ethyl cellulose/Eudragit® RS 
nanoparticles were prepared by the solvent evaporation method. Dexamethasone 
release from the polymeric nanoparticles was investigated in vitro using Franz diffusion 
cells. Drug penetration was assessed ex vivo using excised human skin. Follicular 
penetration of nanoparticles was investigated ex vivo using pig ear skin. 
Eudragit® RS nanoparticles were smaller and positively charged but had a lower 
dexamethasone loading capacity (0.3–0.7%) than ethyl cellulose nanoparticles (1.4–
2.2%). By blending the two polymers (1:1), small (105 nm), positively charged 
(+37 mV) nanoparticles with sufficient dexamethasone loading (1.3%) were obtained. 
Dexamethasone release and penetration significantly decreased with decreasing drug 
                                            
5 Parts of this were taken from: 
1. B. Balzus, F.F. Sahle, S. Hönzke, C. Gerecke, F. Schumacher, S. Hedtrich, B. Kleuser, R. 
Bodmeier, Formulation and ex vivo evaluation of polymeric nanoparticles for controlled delivery 
of corticosteroids to the skin and the corneal epithelium, Eur. J. Pharm. Biopharm., 115 (2017) 
122-130. 
2. B. Balzus, M. Colombo, F.F. Sahle, G. Zoubari, S. Staufenbiel, R. Bodmeier, Comparison of 
different in vitro release methods used to investigate nanocarriers intended for dermal 




to polymer ratio and increased when Eudragit® RS was blended with ethyl cellulose. 
Ex vivo, drug release and penetration from the nanoparticles was slower than a 
conventional cream.  
Ethyl cellulose dissolved fast in artificial sebum, whereas Eudragit® RS was insoluble. 
Artificial sebum increased the drug release from ethyl cellulose nanoparticles, whereas 
it reduced the drug release from Eudragit® RS nanoparticles indicating a sebum-
responsive drug release from ethyl cellulose nanoparticles. The hair follicle penetration 
depth of Eudragit® RS (330 µm) and ethyl cellulose nanoparticles (380 µm) was 
comparable, but the fluorescence intensity inside the hair follicle was higher from Nile 
red-loaded ethyl cellulose nanoparticles compared to Eudragit® RS nanoparticles.  
In conclusion, the prepared nanoparticles showed great potential to control the release 
and penetration of corticosteroids on the skin and in the hair follicle to maximize 
treatment effectiveness. 
The comparison of the different in vitro drug release methods indicated that the 
methods differ in their discriminative power and reproducibility. The in situ 
measurement was a simple and fast method, but not adequately discriminating 
because of a too rapid drug dissolution/release. Franz diffusion cells and dialysis bags 
were in most cases discriminative for the different nanoparticles with the drug 
dissolution/release being in the order of nanocrystals > Eudragit® RS nanoparticles > 
lipid nanoparticles ≥ ethyl cellulose nanoparticles. However, drug release experiments 






Die kontrollierte Abgabe von Kortikosteroiden auf der Haut und im Haarfollikel unter 
Verwendung von Nanopartikeln könnte ihre Nebenwirkungen reduzieren und die 
Wirksamkeit der Behandlung maximieren. Zur Beurteilung der Qualität von 
Nanopartikeln und ihres in vivo Verhaltens, ist die Untersuchung der in vitro 
Freisetzung eine der wichtigsten Methoden. 
Es sollten mit Dexamethason beladene Polymernanopartikel hergestellt werden, die 
gut auf der Haut haften und den Arzneistoff langsam und kontrolliert freisetzen. 
Zusätzlich sollten Talg sensitive Nanopartikel hergestellt werden, die in der Lage sind, 
tief in den Haarfollikel einzudringen und durch ihre Auflösung im Talg den Arzneistoff 
freizusetzen. 
Die diskriminierenden Eigenschaften und die Reproduzierbarkeit der folgenden drei in 
vitro Freisetzungsmethoden für Nanopartikel sollten bewertet werden: Dialysebeutel, 
Franz-Diffusionszellen und eine in situ Freisetzungsmethode mit dem Sirius® inForm. 
Die untersuchten Nanopartikel waren Nanokristalle, Polymernanopartikel und 
Lipidnanopartikel. 
Mit Dexamethason beladene Ethylcellulose, Eudragit® RS und Ethylcellulose / 
Eudragit® RS-Nanopartikel wurden durch das Lösungsmittelverdampfungsverfahren 
hergestellt. Die Dexamethason-Freisetzung aus den Polymernanopartikeln wurde in 
vitro mit Franz-Diffusionszellen untersucht. Die Arzneistoffpenetration wurde ex vivo 
unter Verwendung von exzidierter menschlicher Haut ermittelt. Die follikulare 
Penetration von Nanopartikeln wurde ex vivo unter Verwendung von Schweineohrhaut 
untersucht. 
                                            
6 Teile dieses Abschnittes wurden entnommen aus: 
1. B. Balzus, F.F. Sahle, S. Hönzke, C. Gerecke, F. Schumacher, S. Hedtrich, B. Kleuser, R. 
Bodmeier, Formulation and ex vivo evaluation of polymeric nanoparticles for controlled delivery 
of corticosteroids to the skin and the corneal epithelium, Eur. J. Pharm. Biopharm., 115 (2017) 
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